ehc-20211027

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): October 27, 2021

Encompass Health Corporation

(Exact name of Registrant as specified in its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)


001-10315			63-0860407
(Commission File Number)			(IRS Employer Identification No.)

9001 Liberty Parkway, Birmingham, Alabama 35242

(Address of Principal Executive Offices, Including Zip Code)

(205) 967-7116

(Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	EHC	New York Stock Exchange

The information contained herein is being furnished pursuant to Item 2.02 of Form 8‑K, “Results of Operations and Financial Condition,” and Item 7.01 of Form 8-K, “Regulation FD Disclosure.” This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

ITEM 2.02. Results of Operations and Financial Condition.

On October 27, 2021, Encompass Health Corporation (“Encompass Health” or the “Company”) issued a press release reporting the financial results of the Company for the three and nine months ended September 30, 2021. A copy of the press release is attached to this report as Exhibit 99.1 and incorporated herein by reference.

The Company uses “same-store” comparisons to explain the changes in certain performance metrics and line items within its financial statements. Same-store comparisons are calculated based on hospitals open throughout both the full current and prior periods presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company's results of operations.

ITEM 7.01. Regulation FD Disclosure.

See Item 2.02, “Results of Operations and Financial Condition,” above.

In addition, a copy of the supplemental information which will be discussed during the Company’s earnings call at 10:00 a.m. Eastern Time on Thursday, October 28, 2021 is attached to this report as Exhibit 99.2 and incorporated herein by reference.

Note Regarding Presentation of Non-GAAP Financial Measures

The Company is providing adjusted earnings per share from continuing operations attributable to Encompass Health (“adjusted earnings per share”). The Company believes the presentation of adjusted earnings per share provides useful additional information to investors because it provides better comparability of ongoing operating performance to prior periods given that it excludes the impact of government, class action, and related settlements; professional fees—accounting, tax, and legal; mark-to-market adjustments for stock appreciation rights; gains or losses related to hedging and equity instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); items related to corporate and facility restructurings; and certain other items the Company believes to be non-indicative of its ongoing operating performance. It is reasonable to expect that one or more of these excluded items will occur in future periods, but the amounts recognized can vary significantly from period to period and may not directly relate to the Company’s ongoing operating performance. Accordingly, they can complicate comparisons of the Company’s results of operations across periods and comparisons of the Company’s results to those of other healthcare companies. Adjusted earnings per share should not be considered as a measure of financial performance under generally accepted accounting principles in the United States (“GAAP”) as the items excluded from it are significant components in understanding and assessing financial performance. Because adjusted earnings per share is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, it may not be comparable as presented to other similarly titled measures of other companies. The Company reconciles adjusted earnings per share to earnings per share in the press release attached as Exhibit 99.1 and the supplemental information attached as Exhibit 99.2.

The leverage ratio referenced therein is defined as the ratio of consolidated total debt to Adjusted EBITDA for the trailing four quarters. The Company believes its leverage ratio and Adjusted EBITDA are measures of its ability to service its debt and its ability to make capital expenditures. Additionally, the leverage ratio is a standard measurement used by investors to gauge the creditworthiness of an institution. The Company’s credit agreement also includes a maximum leverage ratio financial covenant which allows the Company to deduct up to $300 million of cash on hand from consolidated total debt. The Company reconciles Adjusted EBITDA to net income and to net cash provided by operating activities in the press release attached as Exhibit 99.1 and the supplemental information attached as Exhibit 99.2. Adjusted EBITDA for the Company’s reportable segments is reconciled to net income from continuing operations before income tax expense in the press release attached as Exhibit 99.1 and the supplemental information attached as Exhibit 99.2.

The Company uses Adjusted EBITDA on a consolidated basis as a liquidity measure. The Company believes this financial measure on a consolidated basis is important in analyzing its liquidity because it is the key component of certain material covenants contained within the Company’s credit agreement, which is discussed in more detail in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, “Liquidity and Capital Resources,” and Note 10, Long-term Debt, to the consolidated financial statements included in its Annual Report on Form 10‑K for the year ended December 31, 2020 (the “2020 Form 10‑K”). These covenants are material terms of the credit agreement. Noncompliance with these financial covenants under the credit agreement—its interest coverage ratio and its leverage ratio—could result in the Company’s lenders requiring the Company to immediately repay all amounts borrowed. If the Company anticipated a potential covenant violation, it would seek relief from its lenders, which would have some cost to the Company, and such relief might be on terms less favorable to those in the Company’s existing credit agreement. In addition, if the Company cannot satisfy these financial covenants, it would be prohibited under the credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying common stock dividends, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA is critical to the Company’s assessment of its liquidity.

In general terms, the credit agreement definition of Adjusted EBITDA, therein referred to as “Adjusted Consolidated EBITDA,” allows the Company to add back to consolidated net income interest expense, income taxes, and depreciation and amortization and then add back to consolidated net income (1) all unusual or nonrecurring items reducing consolidated net income (of which only up to $10 million in a year may be cash expenditures), (2) any losses from discontinued operations, (3) non-ordinary course fees, costs and expenses incurred with respect to any litigation or settlement, (4) share-based compensation expense, (5) costs and expenses associated with changes in the fair value of marketable securities, (6) costs and expenses associated with the issuance or prepayment debt and acquisitions, and (7) any restructuring charges not in excess of 20% of Adjusted Consolidated EBITDA. The Company also subtracts from consolidated net income all unusual or nonrecurring items to the extent they increase consolidated net income.

The calculation of Adjusted EBITDA under the credit agreement does not require us to deduct net income attributable to noncontrolling interests or gains on fair value adjustments of hedging and equity instruments, disposal of assets, and development activities. It also does not allow us to add back losses on fair value adjustments of hedging instruments or unusual or nonrecurring cash expenditures in excess of $10 million. These items and amounts, in addition to the items falling within the credit agreement’s “unusual or nonrecurring” classification, may occur in future periods, but can vary significantly from period to period and may not directly relate to, or be indicative of, the Company's ongoing liquidity or operating performance. Accordingly, the Adjusted EBITDA calculation presented here includes adjustments for them.

Adjusted EBITDA is not a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Therefore, Adjusted EBITDA should not be considered a substitute for net income or cash flows from operating, investing, or financing activities. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. Revenues and expenses are measured in accordance with the policies and procedures described in Note 1, Summary of Significant Accounting Policies, to the consolidated financial statements accompanying the 2020 Form 10-K.

The Company also uses adjusted free cash flow as an analytical indicator to assess its performance. Management believes the presentation of adjusted free cash flow provides investors an efficient means by which they can evaluate the Company’s capacity to reduce debt, pursue development activities, and return capital to its common stockholders. The calculation of adjusted free cash flow and a reconciliation of net cash provided by operating activities to adjusted free cash flow are included in the press release attached as Exhibit 99.1 and the supplemental information attached as Exhibit 99.2. This measure is not a defined measure of financial performance under GAAP and should not be considered as an alternative to net cash provided by operating activities. The Company’s definition of adjusted free cash flow is limited and does not represent residual cash flows available for discretionary spending. Because this measure is not determined in accordance with GAAP and is susceptible to varying calculations, it may not be comparable to other similarly titled measures presented by other companies. See the consolidated statements of cash flows included in the 2020 Form 10-K and the condensed consolidated statements of cash flows included in the Company's quarterly report on Form 10-Q for the quarterly period ended September 30, 2021 (the “September 2021 Form 10-Q”), when filed, and in the press release attached as Exhibit 99.1 for the GAAP measures of cash flows from operating, investing, and financing activities.

Forward-Looking Statements

The information contained in the press release and supplemental information includes certain estimates, projections, and other forward-looking statements that involve known and unknown risks and relate to, among other things, future events, including the ongoing strategic review and its impact on the business model, outlook and guidance, the expected impact of the COVID-19 pandemic on Encompass Health’s business and financial assumptions, the Company’s business strategy, financial plans, dividend strategies or payments, effective income tax rates, plans to repurchase its debt or equity securities, future financial performance, projected business results or model, ability to return value to its shareholders, projected capital expenditures, leverage ratio, acquisition opportunities, and the impact of future legislation or regulation. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “targets,” “potential,” or “continue” or the negative of these terms or other comparable terminology. These estimates, projections, and other forward-looking statements are based on assumptions the Company believes, as of the date hereof, are reasonable. Inevitably, there will be differences between such estimates and actual results, and those differences may be material.

There can be no assurance that any estimates, projections, or forward-looking statements will be realized.

All such estimates, projections, and forward-looking statements speak only as of the date hereof. The Company undertakes no duty to publicly update or revise that information.

You are cautioned not to place undue reliance on the estimates, projections, and other forward-looking statements in this report, the press release, and supplemental information as they are based on current expectations and general assumptions and are subject to various risks, uncertainties, and other factors, including those set forth in the attached press release and in the 2020 Form 10‑K, the September 2021 Form 10-Q when filed, and in other documents the Company previously filed with the SEC, many of which are beyond the Company’s control. These factors may cause actual results to differ materially from the views, beliefs, and estimates expressed herein.

ITEM 9.01. Financial Statements and Exhibits.

(d) Exhibits.


Exhibit Number						Description
99.1						Press release of Encompass Health Corporation, dated October 27, 2021.
99.2						Supplemental information provided in connection with the third quarter 2021 earnings call of Encompass Health Corporation.
104						Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the Inline XBRL document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.


ENCOMPASS HEALTH CORPORATION
By:	/S/ DOUGLAS E. COLTHARP
	Name:	Douglas E. Coltharp
	Title:	Executive Vice President and Chief Financial Officer

Dated: October 27, 2021

Exhibit 99.1


Media Contact			October 27, 2021
Casey Winger, 205 447-6410
[email protected]

Investor Relations Contact
Mark Miller, 205 970-5860
[email protected]

Encompass Health reports results for third quarter 2021

Revises full-year guidance for 2021

BIRMINGHAM, Ala. - Encompass Health Corporation (NYSE: EHC), a national leader in integrated healthcare, offering facility-based and home-based patient care through its network of inpatient rehabilitation hospitals and home health and hospice agencies, today reported its results of operations for the third quarter ended September 30, 2021.

“Our consolidated financial results for the third quarter were solid, with year-over-year growth in revenues and Adjusted EBITDA. Our inpatient rehabilitation business continued to experience strong revenue and Adjusted EBITDA growth in spite of labor challenges," said President and Chief Executive Officer of Encompass Health Mark Tarr. "Our home health and hospice business experienced COVID-related headwinds which limited volume growth and increased costs. We remain very confident in the long-term trends for each of our businesses and in our competitive position. Although we have seen improvement in operating trends during October, we are lowering our full-year 2021 guidance as a result of the current and we believe transient challenges."

Consolidated results


					Growth
	Q3 2021		Q3 2020		Dollars		Percent
	(In Millions, Except Per Share Data)
Net operating revenues	$	1,284.8	$	1,173.9	$	110.9	9.4	%
Income from continuing operations attributable to Encompass Health per diluted share	1.00		0.78		0.22		28.2	%
Adjusted earnings per share	1.03		0.78		0.25		32.1	%
Cash flows provided by operating activities	177.6		173.4		4.2		2.4	%
Adjusted EBITDA	245.6		230.2		15.4		6.7	%
Adjusted free cash flow	124.1		124.1		—		—	%
	Nine Months Ended September 30,
	2021		2020
Cash flows provided by operating activities	$	592.0	$	425.0	$	167.0	39.3	%
Adjusted free cash flow	437.1		366.9		70.2		19.1	%


						1

Revenue growth resulted from strong discharge growth and favorable pricing in our inpatient rehabilitation segment, partly offset by volume and cost headwinds in the home health and hospice business.

The increase in income from continuing operations attributable to Encompass Health per diluted share and adjusted earnings per share in 2021 primarily resulted from revenue growth.

The increase in year-to-date cash flows provided by operating activities and adjusted free cash flow primarily resulted from revenue growth and the lower maintenance capital expenditures in 2021, partly offset by higher cash taxes paid year-to-date in 2021.

See attached supplemental information for calculations of non-GAAP measures and reconciliations to their most comparable GAAP measure.

Inpatient rehabilitation segment results


							Growth
	Q3 2021			Q3 2020			Dollars		Percent
Net operating revenues:	(In Millions)
Inpatient	$	983.7		$	883.2		$	100.5	11.4	%
Outpatient and other	27.2			16.2			11.0		67.9	%
Total segment revenue	$	1,010.9		$	899.4		$	111.5	12.4	%

	(Actual Amounts)
Discharges	49,983			45,962			4,021		8.7	%

Same-store discharge growth									6.7	%
Net patient revenue per discharge	$	19,681		$	19,216		$	465	2.4	%
Revenue reserves related to bad debt as a percent of revenue	2.0		%	1.4		%			60 basis points

	(In Millions)
Adjusted EBITDA	$	231.6		$	209.2		$	22.4	10.7	%

•Revenue – Inpatient revenue growth resulted from increased volumes and pricing. Total discharge growth for the third quarter of 2021 was 8.7% with same-store growth of 6.7%. Revenue reserves related to bad debt as a percent of revenue increased 60 basis points primarily attributable to claims processing delays by managed care payors.

Growth in net patient revenue per discharge of 2.4% primarily resulted from an increase in reimbursement rates and higher patient acuity.

The increase in outpatient and other revenue included an increase of $11.3 million in provider tax revenues (offset by an increase of approximately $9.3 million in provider tax expenses included in other operating expenses).

•Adjusted EBITDA – The 10.7% increase in Adjusted EBITDA in the third quarter of 2021 primarily resulted from revenue growth partially offset by higher expenses.


						2

Home health and hospice segment results


					Growth
	Q3 2021		Q3 2020		Dollars		Percent
Net operating revenues:	(In Millions)
Home health revenue	$	221.1	$	223.3	$	(2.2)	(1.0)	%
Hospice revenue	52.8		51.2		1.6		3.1	%
Total segment revenue	$	273.9	$	274.5	$	(0.6)	(0.2)	%

Adjusted EBITDA	$	46.4	$	51.8	$	(5.4)	(10.4)	%

Home Health
Starts of care:	(Actual Amounts)
Episodic admissions	37,577		40,765		(3,188)		(7.8)	%
Same-store episodic admissions growth							(9.7)	%
Episodic recertifications	27,742		29,830		(2,088)		(7.0)	%
Total episodic starts of care	65,319		70,595		(5,276)		(7.5)	%

Total admissions	48,412		48,838		(426)		(0.9)	%
Same-store total admissions growth							(2.7)	%
Total recertifications	32,942		33,786		(844)		(2.5)	%
Total starts of care	81,354		82,624		(1,270)		(1.5)	%
Revenue per episode	$	2,916	$	2,910	$	6	0.2	%

Hospice
Admissions:
Same store	2,884		3,354		(470)		(14.0)	%
New store	378		—		378		11.3	%
Total admissions	3,262		3,354		(92)		(2.7)	%

•Revenue – Total admissions were down 0.9% and same-store admissions were down 2.7%. The decline in admissions was attributable primarily to COVID-related challenges.

Home health revenue per episode increased 0.2%, less than expected, due to the mix between early and late payment periods resulting from the decline of episodic admissions during the quarter.

•Adjusted EBITDA - The 10.4% decrease in Adjusted EBITDA resulted primarily from COVID-related challenges that limited volume and increased expenses.


						3

General and administrative expenses


	Q3 2021		% of Consolidated Revenue	Q3 2020		% of Consolidated Revenue
	(In Millions)
General and administrative expenses, excluding stock-based compensation	$	32.4	2.5%	$	30.8	2.6%

General and administrative expenses decreased as a percent of consolidated revenue primarily due to the increased revenue base year-over-year.

General and administrative expenses in the above table exclude $4.6 million in costs associated with the strategic alternatives review of the Company's home health and hospice business for the third quarter of 2021.

2021 guidance

The Company revised its full-year guidance as follows:


	Full-Year 2021 Guidance Ranges
	Previous Guidance	Updated Guidance
	(In Millions, Except Per Share Data)
Net operating revenues	$5,100 to $5,250	$5,080 to $5,130
Adjusted EBITDA	$1,050 to $1,070	$1,025 to $1,045
Adjusted earnings per share from continuing operations attributable to Encompass Health	$4.32 to $4.47	$4.23 to $4.38

The Company's 2021 guidance assumes the continuation of the current structure of the business for 2021.

For additional considerations regarding the Company's 2021 guidance ranges, see the supplemental information posted on the Company's website at http://investor.encompasshealth.com. See also the “Other information” section below for an explanation of why the Company does not provide guidance for comparable GAAP measures for Adjusted EBITDA and adjusted earnings per share.

Update on Strategic Alternatives Review for Home Health and Hospice Business

The Company expects to effect the partial or full separation of its home health and hospice business into an independent public company via a carve-out IPO, spin-off, or split-off. The Company is targeting such a transaction in the first half of 2022 and expects to announce a more precise timing and the form of the separation transaction in connection with its fourth quarter earnings release. While there can be no assurance that a transaction of this nature will be consummated, the Company has made significant progress on the various tasks necessary to complete a separation transaction and will further its state of readiness over the balance of this year.

The Company has previously indicated that it believes that a full or partial separation of the home health and hospice business will enhance the long-term success and value of the business. The Company has thoroughly evaluated a broad array of public and private transaction alternatives and believes that effecting the separation via the formation of an independent public company is superior to the other alternatives considered. Among other considerations, this belief is based on the anticipated strategic focus, future growth and value creating opportunities, execution risks, and tax efficiency resulting from such a transaction.

As the Company has previously reported, many of the key preparatory actions for a separation have been completed, including but not limited to, audited carve-out financial statements for the home health and hospice business, a confidential submission of a draft registration statement on Form S-1 with the United States Securities and Exchange Commission and certain required regulatory filings.


						4

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of that jurisdiction.

Earnings conference call and webcast

The Company will host an investor conference call at 10:00 a.m. Eastern Time on Thursday, October 28, 2021 to discuss its results for the third quarter of 2021. For reference during the call, the Company will post certain supplemental information at http://investor.encompasshealth.com.

The conference call may be accessed by dialing 800 347-7407 and giving the pass code EHCQ321. International callers should dial 203 518-9704 and give the same pass code. Please call approximately ten minutes before the start of the call to ensure you are connected. The conference call will also be webcast live and will be available for on-line replay at http://investor.encompasshealth.com by clicking on an available link.

About Encompass Health

As a national leader in integrated healthcare services, Encompass Health (NYSE: EHC) offers both facility-based and home-based patient care through its network of inpatient rehabilitation hospitals, home health agencies and hospice agencies. With a national footprint that includes 145 hospitals and 249 home health locations and 95 hospice locations in 42 states and Puerto Rico, the Company provides high-quality, cost-effective integrated healthcare. Encompass Health is ranked as one of Fortune's 100 Best Companies to Work For. For more information, visit encompasshealth.com, or follow us on our newsroom, Twitter, Instagram and Facebook.

Other information

The information in this press release is summarized and should be read in conjunction with the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 (the “September 2021 Form 10-Q”), when filed, as well as the Company's Current Report on Form 8-K filed on October 27, 2021 (the “Q3 Earnings Form 8-K”), to which this press release is attached as Exhibit 99.1. In addition, the Company will post supplemental information today on its website at http://investor.encompasshealth.com for reference during its October 28, 2021 earnings call.

The financial data contained in the press release and supplemental information include non-GAAP financial measures, including the Company’s adjusted earnings per share, leverage ratio, Adjusted EBITDA, and adjusted free cash flow. Reconciliations to their most comparable GAAP measure, except with regard to non-GAAP guidance, are included below or in the Q3 Earnings Form 8-K. Readers are encouraged to review the “Note Regarding Presentation of Non-GAAP Financial Measures” included in the Q3 Earnings Form 8-K which provides further explanation and disclosure regarding the Company’s use of these non-GAAP financial measures.

Excluding net operating revenues, the Company does not provide guidance on a GAAP basis because it is unable to predict, with reasonable certainty, the future impact of items that are deemed to be outside the control of the Company or otherwise non-indicative of its ongoing operating performance. Such items include government, class action, and related settlements; professional fees—accounting, tax, and legal; mark-to-market adjustments for stock appreciation rights; gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); items related to corporate and facility restructurings; and certain other items the Company believes to be non-indicative of its ongoing operations. These items cannot be reasonably predicted and will depend on several factors, including industry and market conditions, and could be material to the Company's results computed in accordance with GAAP.


						5

However, the following reasonably estimable GAAP measures for 2021 would be included in a reconciliation for Adjusted EBITDA if the other reconciling GAAP measures could be reasonably predicted:

•Interest expense and amortization of debt discounts and fees - estimate of $160 million to $170 million

•Amortization of debt-related items - approximately $5 million

The Q3 Earnings Form 8-K and, when filed, the September 2021 Form 10-Q can be found on the Company's website at http://investor.encompasshealth.com and the SEC's website at www.sec.gov.


						6

Encompass Health Corporation and Subsidiaries

Condensed Consolidated Statements of Comprehensive Income

(Unaudited)


	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
	(In Millions, Except Per Share Data)
Net operating revenues	$	1,284.8	$	1,173.9	$	3,802.9	$	3,430.0
Operating expenses:
Salaries and benefits	730.1		664.9		2,125.5		1,995.9
Other operating expenses	173.4		163.4		508.4		471.3
Occupancy costs	19.8		20.3		60.2		60.8
Supplies	53.2		52.5		155.1		148.8
General and administrative expenses	43.9		39.1		136.7		117.7
Depreciation and amortization	64.9		61.2		190.8		180.7
Government, class action, and related settlements	—		—		—		2.8

Total operating expenses	1,085.3		1,001.4		3,176.7		2,978.0
Loss on early extinguishment of debt	—		—		1.0		—
Interest expense and amortization of debt discounts and fees	39.9		49.0		124.5		138.0
Other income	(0.4)		(2.5)		(6.4)		(6.4)
Equity in net income of nonconsolidated affiliates	(0.9)		(1.0)		(2.9)		(2.5)
Income from continuing operations before income tax expense	160.9		127.0		510.0		322.9
Provision for income tax expense	34.1		26.9		108.1		65.8
Income from continuing operations	126.8		100.1		401.9		257.1
Loss from discontinued operations, net of tax	(0.1)		—		(0.4)		—
Net and comprehensive income	126.7		100.1		401.5		257.1
Less: Net and comprehensive income attributable to noncontrolling interests	(26.7)		(22.4)		(80.9)		(58.9)
Net and comprehensive income attributable to Encompass Health	$	100.0	$	77.7	$	320.6	$	198.2



Weighted average common shares outstanding:
Basic	99.0		98.7		99.0		98.5
Diluted	100.2		99.9		100.1		99.7
Earnings per common share:
Basic earnings per share attributable to Encompass Health common shareholders:
Continuing operations	$	1.01	$	0.78	$	3.22	$	2.01
Discontinued operations	—		—		—		—
Net income	$	1.01	$	0.78	$	3.22	$	2.01
Diluted earnings per share attributable to Encompass Health common shareholders:
Continuing operations	$	1.00	$	0.78	$	3.20	$	1.99
Discontinued operations	—		—		—		—
Net income	$	1.00	$	0.78	$	3.20	$	1.99

Amounts attributable to Encompass Health common shareholders:
Income from continuing operations	$	100.1	$	77.7	$	321.0	$	198.2
Loss from discontinued operations, net of tax	(0.1)		—		(0.4)		—
Net income attributable to Encompass Health	$	100.0	$	77.7	$	320.6	$	198.2


						7

Encompass Health Corporation and Subsidiaries

Condensed Consolidated Balance Sheets

(Unaudited)


	September 30, 2021		December 31, 2020
	(In Millions)
Assets
Current assets:
Cash and cash equivalents	$	94.8	$	224.0
Restricted cash	75.9		65.4
Accounts receivable	637.8		572.8
Other current assets	101.3		86.4
Total current assets	909.8		948.6
Property and equipment, net	2,467.9		2,206.6
Operating lease right-of-use assets	239.0		245.7
Goodwill	2,417.6		2,318.7
Intangible assets, net	424.3		431.3

Other long-term assets	263.1		295.0
Total assets	$	6,721.7	$	6,445.9
Liabilities and Shareholders’ Equity
Current liabilities:
Current portion of long-term debt	$	65.9	$	38.3
Current operating lease liabilities	40.7		44.8
Accounts payable	149.4		115.0


Accrued expenses and other current liabilities	537.9		519.2
Total current liabilities	793.9		717.3
Long-term debt, net of current portion	3,142.0		3,250.6
Long-term operating lease liabilities	208.4		209.6

Deferred income tax liabilities	60.4		51.8
Other long-term liabilities	223.5		215.0
	4,428.2		4,444.3
Commitments and contingencies

Redeemable noncontrolling interests	32.5		31.6
Shareholders’ equity:
Encompass Health shareholders’ equity	1,842.7		1,588.0
Noncontrolling interests	418.3		382.0
Total shareholders’ equity	2,261.0		1,970.0
Total liabilities and shareholders’ equity	$	6,721.7	$	6,445.9


						8

Encompass Health Corporation and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(Unaudited)


	Nine Months Ended September 30,
	2021		2020
	(In Millions)
Cash flows from operating activities:
Net income	$	401.5	$	257.1
Loss from discontinued operations, net of tax	0.4		—
Adjustments to reconcile net income to net cash provided by operating activities—

Depreciation and amortization	190.8		180.7
Loss on early extinguishment of debt	1.0		—


Stock-based compensation	21.7		25.3
Deferred tax expense (benefit)	4.4		(5.7)

Other, net	(0.2)		15.5
Changes in assets and liabilities, net of acquisitions—
Accounts receivable	(36.7)		(71.8)
Other assets	(27.0)		17.3
Accounts payable	8.8		10.3
Accrued payroll	30.0		86.7
Accrued interest payable	(23.0)		(0.2)
Other liabilities	20.9		(90.0)
Net cash used in operating activities of discontinued operations	(0.6)		(0.2)
Total adjustments	190.1		167.9
Net cash provided by operating activities	592.0		425.0
Cash flows from investing activities:
Acquisition of businesses, net of cash acquired	(98.8)		(1.1)
Purchases of property and equipment	(336.3)		(256.2)
Additions to capitalized software costs	(13.0)		(5.7)





Proceeds from disposal of assets	18.5		0.1
Other, net	(16.0)		(1.9)

Net cash used in investing activities	(445.6)		(264.8)


			(Continued)			9

Encompass Health Corporation and Subsidiaries

Condensed Consolidated Statements of Cash Flows (Continued)

(Unaudited)


	Nine Months Ended September 30,
	2021		2020
	(In Millions)
Cash flows from financing activities:
Proceeds from bond issuance	—		592.5
Principal payments on debt, including pre-payments	(210.9)		(14.7)

Borrowings on revolving credit facility	110.0		330.0
Payments on revolving credit facility	(20.0)		(375.0)
Principal payments under finance lease obligations	(18.6)		(16.7)
Debt amendment and issuance costs	—		(13.5)
Taxes paid on behalf of employees for shares withheld	(16.4)		(15.7)
Contributions from consolidated affiliates	36.1		24.7
Dividends paid on common stock	(84.7)		(84.3)
Distributions paid to noncontrolling interests of consolidated affiliates	(77.8)		(52.9)
Repurchases of common stock, including fees and expenses	—		(4.9)
Purchase of equity interests in consolidated affiliates	—		(162.3)
Other, net	(0.1)		1.1
Net cash (used in) provided by financing activities	(282.4)		208.3
(Decrease) increase in cash, cash equivalents, and restricted cash	(136.0)		368.5
Cash, cash equivalents, and restricted cash at beginning of year	310.9		159.6
Cash, cash equivalents, and restricted cash at end of year	$	174.9	$	528.1

Reconciliation of Cash, Cash Equivalents, and Restricted Cash
Cash and cash equivalents at beginning of period	$	224.0	$	94.8
Restricted cash at beginning of period	65.4		57.4
Restricted cash included in other long-term assets at beginning of period	21.5		7.4
Cash, cash equivalents, and restricted cash at beginning of period	$	310.9	$	159.6

Cash and cash equivalents at end of period	$	94.8	$	450.0
Restricted cash at end of period	75.9		57.2
Restricted cash included in other long-term assets at end of period	4.2		20.9
Cash, cash equivalents, and restricted cash at end of period	$	174.9	$	528.1

Supplemental schedule of noncash operating, investing and financing activities:
Property and equipment additions through finance leases	$	46.2	$	5.1
Accrued purchases of property & equipment	25.5		14.7
Operating lease additions	32.2		21.2


						10

Encompass Health Corporation and Subsidiaries

Supplemental Information

Earnings Per Share


	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
	(In Millions, Except Per Share Data)
Adjusted EBITDA	$	245.6	$	230.2	$	775.3	$	620.4
Depreciation and amortization	(64.9)		(61.2)		(190.8)		(180.7)
Interest expense and amortization of debt discounts and fees	(39.9)		(49.0)		(124.5)		(138.0)
Stock-based compensation expense	(6.9)		(8.3)		(21.7)		(25.3)
Gain (loss) on disposal or impairment of assets	5.2		(7.5)		2.4		(10.6)
	139.1		104.2		440.7		265.8
Certain items non-indicative of ongoing operating performance:

Loss on early extinguishment of debt	—		—		(1.0)		—
Costs associated with the strategic alternatives review	(4.6)		—		(9.6)		—
Costs associated with the Frontier acquisition	—		—		(1.3)		—
Gain on consolidation of former equity method location	—		—		—		2.2

Change in fair market value of equity securities	(0.3)		0.4		0.3		0.3

Government, class action, and related settlements	—		—		—		(2.8)
Payroll taxes on SARs exercise	—		—		—		(1.5)
Pre-tax income	134.2		104.6		429.1		264.0
Income tax expense	(34.1)		(26.9)		(108.1)		(65.8)
Income from continuing operations (1)	$	100.1	$	77.7	$	321.0	$	198.2

Basic shares	99.0		98.7		99.0		98.5
Diluted shares	100.2		99.9		100.1		99.7

Basic earnings per share (1)	$	1.01	$	0.78	$	3.22	$	2.01
Diluted earnings per share (1)	$	1.00	$	0.78	$	3.20	$	1.99

(1)Income from continuing operations attributable to Encompass Health


						11

Encompass Health Corporation and Subsidiaries

Supplemental Information

Adjusted Earnings Per Share


	Q3				9 Months
	2021		2020		2021		2020

Earnings per share, as reported	$	1.00	$	0.78	$	3.20	$	1.99
Adjustments, net of tax:
Government, class action, and related settlements	—		—		—		0.02


Costs associated with the strategic alternatives review	0.03		—		0.07		—
Costs associated with the Frontier acquisition	—		—		0.01		—
Income tax adjustments	—		—		(0.04)		(0.05)


Loss on early extinguishment of debt	—		—		0.01		—

Gain on consolidation of former equity method location	—		—		—		(0.02)
Payroll taxes on SARs exercise	—		—		—		0.01
Adjusted earnings per share*	$	1.03	$	0.78	$	3.26	$	1.96

* Adjusted EPS may not sum due to rounding.


						12

Encompass Health Corporation and Subsidiaries

Supplemental Information

Adjusted Earnings Per Share


	For the Three Months Ended September 30, 2021
			Adjustments
	As Reported		Income Tax Adjustments		Costs Associated with the Strategic Alternatives Review		Change in Fair Market Value of Equity Securities		As Adjusted
	(In Millions, Except Per Share Amounts)
Adjusted EBITDA*	$	245.6	$	—	$	—	$	—	$	245.6
Depreciation and amortization	(64.9)		—		—		—		(64.9)
Interest expense and amortization of debt discounts and fees	(39.9)		—		—		—		(39.9)
Stock-based compensation	(6.9)		—		—		—		(6.9)
Gain on disposal or impairments of assets	5.2		—		—		—		5.2


Costs associated with the strategic alternatives review	(4.6)		—		4.6		—		—



Change in fair market value of equity securities	(0.3)		—		—		0.3		—



Income from continuing operations before income tax expense	134.2		—		4.6		0.3		139.1
Provision for income tax expense	(34.1)		(0.2)		(1.2)		(0.1)		(35.6)
Income from continuing operations attributable to Encompass Health	$	100.1	$	(0.2)	$	3.4	$	0.2	$	103.5



Diluted earnings per share from continuing operations**	$	1.00	$	—	$	0.03	$	—	$	1.03
Diluted shares used in calculation	100.2

* Reconciliation to GAAP provided on page 17

** Adjusted EPS may not sum across due to rounding.


						13

Encompass Health Corporation and Subsidiaries

Supplemental Information

Adjusted Earnings Per Share


	For the Three Months Ended September 30, 2020
			Adjustments
	As Reported		Income Tax Adjustments		Change in Fair Market Value of Equity Securities		As Adjusted
	(In Millions, Except Per Share Amounts)
Adjusted EBITDA*	$	230.2	$	—	$	—	$	230.2
Depreciation and amortization	(61.2)		—		—		(61.2)
Interest expense and amortization of debt discounts and fees	(49.0)		—		—		(49.0)
Stock-based compensation	(8.3)		—		—		(8.3)
Loss on disposal or impairments of assets	(7.5)		—		—		(7.5)





Change in fair market value of equity securities	0.4		—		(0.4)		—



Income from continuing operations before income tax expense	104.6		—		(0.4)		104.2
Provision for income tax expense	(26.9)		0.1		0.1		(26.7)
Income from continuing operations attributable to Encompass Health	$	77.7	$	0.1	$	(0.3)	$	77.5



Diluted earnings per share from continuing operations**	$	0.78	$	—	$	—	$	0.78
Diluted shares used in calculation	99.9

* Reconciliation to GAAP provided on page 17

** Adjusted EPS may not sum across due to rounding.


						14

Encompass Health Corporation and Subsidiaries

Supplemental Information

Adjusted Earnings Per Share


	For the Nine Months Ended September 30, 2021
			Adjustments
	As Reported		Loss on Early Exting. of Debt		Income Tax Adjustments		Costs Associated with the Strategic Alternatives Review		Costs Associated with the Frontier Acquisition		Change in Fair Market Value of Equity Securities		As Adjusted
	(In Millions, Except Per Share Amounts)
Adjusted EBITDA*	$	775.3	$	—	$	—	$	—	$	—	$	—	$	775.3
Depreciation and amortization	(190.8)		—		—		—		—		—		(190.8)


Loss on early extinguishment of debt	(1.0)		1.0		—		—		—		—		—
Interest expense and amortization of debt discounts and fees	(124.5)		—		—		—		—		—		(124.5)
Stock-based compensation	(21.7)		—		—		—		—		—		(21.7)
Gain on disposal or impairment of assets	2.4		—		—		—		—		—		2.4
Costs associated with the strategic alternatives review	(9.6)		—		—		9.6		—		—		—
Costs associated with the Frontier acquisition	(1.3)		—		—		—		1.3		—		—

Change in fair market value of equity securities	0.3		—		—		—		—		(0.3)		—


Income from continuing operations before income tax expense	429.1		1.0		—		9.6		1.3		(0.3)		440.7
Provision for income tax expense	(108.1)		(0.3)		(3.6)		(2.5)		(0.3)		0.1		(114.7)
Income from continuing operations attributable to Encompass Health	$	321.0	$	0.7	$	(3.6)	$	7.1	$	1.0	$	(0.2)	$	326.0





Diluted earnings per share from continuing operations**	$	3.20	$	0.01	$	(0.04)	$	0.07	$	0.01	$	—	$	3.26
Diluted shares used in calculation	100.1

* Reconciliation to GAAP provided on page 17

** Adjusted EPS may not sum across due to rounding.


						15

Encompass Health Corporation and Subsidiaries

Supplemental Information

Adjusted Earnings Per Share


	For the Nine Months Ended September 30, 2020
			Adjustments
	As Reported		Gov't, Class Action, & Related Settlements		Income Tax Adjustments		Change in Fair Market Value of Equity Securities		Gain on Consolidation of Former Equity Method Location		Payroll Taxes on SARs Exercise		As Adjusted
	(In Millions, Except Per Share Amounts)
Adjusted EBITDA*	$	620.4	$	—	$	—	$	—	$	—	$	—	$	620.4
Depreciation and amortization	(180.7)		—		—		—		—		—		(180.7)
Government, class action, and related settlements	(2.8)		2.8		—		—		—		—		—


Interest expense and amortization of debt discounts and fees	(138.0)		—		—		—		—		—		(138.0)
Stock-based compensation	(25.3)		—		—		—		—		—		(25.3)
Loss on disposal or impairment of assets	(10.6)		—		—		—		—		—		(10.6)


Change in fair market value of equity securities	0.3		—		—		(0.3)		—		—		—
Gain on consolidation of former equity method location	2.2		—		—		—		(2.2)		—		—
Payroll taxes on SARs exercise	(1.5)		—		—		—		—		1.5		—
Income from continuing operations before income tax expense	264.0		2.8		—		(0.3)		(2.2)		1.5		265.8
Provision for income tax expense	(65.8)		(0.7)		(4.6)		0.1		0.6		(0.4)		(70.8)
Income from continuing operations attributable to Encompass Health	$	198.2	$	2.1	$	(4.6)	$	(0.2)	$	(1.6)	$	1.1	$	195.0





Diluted earnings per share from continuing operations**	$	1.99	$	0.02	$	(0.05)	$	—	$	(0.02)	$	0.01	$	1.96
Diluted shares used in calculation	99.7

* Reconciliation to GAAP provided on page 17

** Adjusted EPS may not sum across due to rounding.


						16

Encompass Health Corporation and Subsidiaries

Supplemental Information

Reconciliation of Net Income to Adjusted EBITDA


	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
	(In Millions)
Net income	$	126.7	$	100.1	$	401.5	$	257.1
Loss from discontinued operations, net of tax, attributable to Encompass Health	0.1		—		0.4		—
Net income attributable to noncontrolling interests	(26.7)		(22.4)		(80.9)		(58.9)
Government, class action, and related settlements	—		—		—		2.8

Provision for income tax expense	34.1		26.9		108.1		65.8
Interest expense and amortization of debt discounts and fees	39.9		49.0		124.5		138.0
Depreciation and amortization	64.9		61.2		190.8		180.7
Loss on early extinguishment of debt	—		—		1.0		—
(Gain) loss on disposal or impairment of assets	(5.2)		7.5		(2.4)		10.6
Stock-based compensation expense	6.9		8.3		21.7		25.3
Costs associated with the strategic alternatives review	4.6		—		9.6		—
Costs associated with the Frontier acquisition	—		—		1.3		—
Gain on consolidation of former equity method location	—		—		—		(2.2)


Change in fair market value of equity securities	0.3		(0.4)		(0.3)		(0.3)
Payroll taxes on SARs exercise	—		—		—		1.5
Adjusted EBITDA	$	245.6	$	230.2	$	775.3	$	620.4

Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations

Before Income Tax Expense


	Three Months Ended September 30,				Nine Months Ended September 30,				Year Ended December 31,
	2021		2020		2021		2020		2020
	(In Millions)
Total segment Adjusted EBITDA	$	278.0	$	261.0	$	879.4	$	712.8	$	986.3
General and administrative expenses	(43.9)		(39.1)		(136.7)		(117.7)		(155.5)
Depreciation and amortization	(64.9)		(61.2)		(190.8)		(180.7)		(243.0)
Gain (loss) on disposal or impairment of assets	5.2		(7.5)		2.4		(10.6)		(11.6)
Government, class action, and related settlements	—		—		—		(2.8)		(2.8)

Loss on early extinguishment of debt	—		—		(1.0)		—		(2.3)
Interest expense and amortization of debt discounts and fees	(39.9)		(49.0)		(124.5)		(138.0)		(184.2)
Net income attributable to noncontrolling interests	26.7		22.4		80.9		58.9		84.6

Change in fair market value of equity securities	(0.3)		0.4		0.3		0.3		0.4
Gain on consolidation of former equity method location	—		—		—		2.2		2.2
Payroll taxes on SARs exercise	—		—		—		(1.5)		(1.5)

Income from continuing operations before income tax expense	$	160.9	$	127.0	$	510.0	$	322.9	$	472.6


						17

Encompass Health Corporation and Subsidiaries

Supplemental Information

Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA


	Three Months Ended September 30,				Nine Months Ended September 30,				Year Ended December 31,
	2021		2020		2021		2020		2020
	(In Millions)
Net cash provided by operating activities	$	177.6	$	173.4	$	592.0	$	425.0	$	704.7

Interest expense and amortization of debt discounts and fees	39.9		49.0		124.5		138.0		184.2
Equity in net income of nonconsolidated affiliates	0.9		1.0		2.9		2.5		3.5
Net income attributable to noncontrolling interests in continuing operations	(26.7)		(22.4)		(80.9)		(58.9)		(84.6)
Amortization of debt-related items	(1.8)		(2.0)		(5.8)		(5.1)		(7.2)
Distributions from nonconsolidated affiliates	(0.9)		(0.8)		(2.7)		(2.8)		(3.8)
Current portion of income tax expense	35.9		23.5		103.7		71.5		51.4
Change in assets and liabilities	16.0		7.2		27.0		47.7		7.3
Cash used in operating activities of discontinued operations	—		0.1		0.6		0.2		0.2
Costs associated with the strategic alternatives review	4.6		—		9.6		—		—
Costs associated with the Frontier acquisition	—		—		1.3		—		—

Payroll taxes on SARs exercise	—		—		—		1.5		1.5

Change in fair market value of equity securities	0.3		(0.4)		(0.3)		(0.3)		(0.4)
Other	(0.2)		1.6		3.4		1.1		3.5
Adjusted EBITDA	$	245.6	$	230.2	$	775.3	$	620.4	$	860.3


						18

Encompass Health Corporation and Subsidiaries

Supplemental Information

Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow


	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
	(In Millions)
Net cash provided by operating activities	$	177.6	$	173.4	$	592.0	$	425.0
Impact of discontinued operations	—		0.1		0.6		0.2
Net cash provided by operating activities of continuing operations	177.6		173.5		592.6		425.2
Capital expenditures for maintenance	(32.1)		(34.0)		(85.9)		(107.5)
Distributions paid to noncontrolling interests of consolidated affiliates	(25.1)		(15.4)		(77.8)		(52.9)
Items non-indicative of ongoing operations:

Cash paid for SARs exercise (inclusive of payroll taxes)	—		—		—		102.1
Transaction costs and related assumed liabilities	3.7		—		8.2		—

Adjusted free cash flow	$	124.1	$	124.1	$	437.1	$	366.9

For the three months ended September 30, 2021, net cash used in investing activities was $124.0 million and primarily resulted from capital expenditures. Net cash used in financing activities during the three months ended September 30, 2021 was $18.5 million and primarily resulted from cash dividends paid on common stock and distributions to noncontrolling interests of consolidated affiliates, offset by net debt borrowings.

For the three months ended September 30, 2020, net cash used in investing activities was $89.7 million and primarily resulted from capital expenditures. Net cash used in financing activities during the three months ended September 30, 2020 was $45.6 million and primarily resulted from cash dividends paid on common stock and distributions paid to noncontrolling interests of consolidated affiliates.

For the nine months ended September 30, 2021, net cash used in investing activities was $445.6 million and primarily resulted from capital expenditures and the acquisition of assets from Frontier Home Health and Hospice. Net cash used in financing activities during the nine months ended September 30, 2021 was $282.4 million and primarily resulted from net debt payments, cash dividends paid on common stock and distributions to noncontrolling interests of consolidated affiliates.

For the nine months ended September 30, 2020, net cash used in investing activities was $264.8 million and primarily resulted from capital expenditures. Net cash provided by financing activities during the nine months ended September 30, 2020 was $208.3 million and primarily resulted from the issuance of additional senior notes in May 2020 offset by the settlement of the final put and exercise of the Home Health Holdings rollover shares and SARs, cash dividends paid on common stock, and distributions paid to noncontrolling interests of consolidated affiliates.


						19

Encompass Health Corporation and Subsidiaries

Forward-Looking Statements

Statements contained in this press release and the supplemental information which are not historical facts, such as those relating to the strategic alternatives review, the nature of the COVID-19 pandemic and its impact on Encompass Health's business and financial assumptions, financial guidance, balance sheet and cash flow plans, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, Encompass Health, through its senior management, may from time to time make forward-looking public statements concerning the matters described herein. All such estimates, projections, and forward-looking information speak only as of the date hereof, and Encompass Health undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information, involve a number of risks and uncertainties, and relate to, among other things, future events, Encompass Health's plan to repurchase its debt or equity securities, dividend strategies, effective income tax rates, its business strategy, its financial plans, its future financial performance, its projected business results or model, its ability to return value to shareholders, its projected capital expenditures, its leverage ratio, its acquisition opportunities, and the impact of future legislation or regulation. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by Encompass Health include, but are not limited to, the possibility that the Company may not be able to realize higher values for its home health and hospice business through strategic transactions; the possibility that the Company may decide not to undertake a transaction following the review of strategic alternatives or that it is not able to consummate any proposed transactions resulting from the review due to, among other things, market, regulatory and other factors; the potential for disruption to the Company's business resulting from the review of strategic alternatives or the undertaking of any transactions following the review; any potential adverse effects of the Company's stock price resulting from the announcement of the results of the strategic review; the continued spread of COVID-19, including the speed, depth, geographic reach and duration of the spread, which could decrease our patient volumes and revenues and lead to staffing and supply shortages and associated cost increases; actions to be taken by the Company in response to the pandemic; the legal, regulatory and administrative developments that occur at the federal, state and local levels; the Company's infectious disease prevention and control efforts; the demand for the Company's services, including based on any downturns in the economy, consumer confidence, or the capital markets and unemployment among family members; the price of Encompass Health's common stock as it affects the Company's willingness and ability to repurchase shares and the financial and accounting effects of any repurchases; any adverse outcome of various lawsuits, claims, and legal or regulatory proceedings involving Encompass Health, including any matters related to yet undiscovered issues, if any, in acquired operations; Encompass Health's ability to attract and retain key management personnel; any adverse effects on Encompass Health's stock price resulting from the integration of acquired operations; potential disruptions, breaches, or other incidents affecting the proper operation, availability, or security of Encompass Health's or its vendors' information systems, including unauthorized access to or theft of patient, business associate, or other sensitive information or inability to provide patient care because of system unavailability as well as unforeseen issues, if any, related to integration of acquired systems; the ability to successfully integrate acquired operations, including realization of anticipated tax benefits, revenues, and cost savings, minimizing the negative impact on margins arising from the changes in staffing and other operating practices, and avoidance of unforeseen exposure to liabilities; Encompass Health's ability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures consistent with its growth strategy; increases in Medicare audit activity, including increased use of sampling and extrapolation, resulting in additional unpaid reimbursement claims and an increase in the backlog of appealed claims denials; changes, delays in (including in connection with resolution of Medicare payment reviews or appeals), or suspension of reimbursement for Encompass Health's services by governmental or private payors; changes in the regulation of the healthcare industry at either or both of the federal and state levels, including as part of national healthcare reform and deficit reduction (such as the Patient-Driven Groupings Model for home health) and Encompass Health's ability to adapt operations to those changes; competitive pressures in the healthcare industry and Encompass Health's response thereto; Encompass Health's ability to obtain and retain favorable arrangements with third-party payors; Encompass Health's ability to control costs,


						20

Encompass Health Corporation and Subsidiaries

Forward-Looking Statements

particularly labor and employee benefit costs, including group medical expenses; adverse effects resulting from coverage determinations made by Medicare Administrative Contractors regarding its Medicare reimbursement claims and lengthening delays in Encompass Health's ability to recover improperly denied claims through the administrative appeals process on a timely basis; Encompass Health's ability to adapt to changes in the healthcare delivery system, including value-based purchasing and involvement in coordinated care initiatives or programs that may arise with its referral sources; Encompass Health's ability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with often severe staffing shortages, which may be worsened by the pandemic, and the impact on Encompass Health's labor expenses from potential union activity and staffing shortages; general conditions in the economy and capital markets, including any instability or uncertainty related to armed conflict or an act of terrorism, governmental impasse over approval of the United States federal budget, an increase in the debt ceiling, or an international sovereign debt crisis; the increase in the costs of defending and insuring against alleged professional liability claims, including claims associated with patient and employee exposures to COVID-19, and Encompass Health's ability to predict the estimated costs related to such claims; and other factors which may be identified from time to time in Encompass Health's SEC filings and other public announcements, including Encompass Health's Form 10‑K for the year ended December 31, 2020 and Form 10-Q for the quarters ended March 31, 2021, June 30, 2021, and September 30, 2021, when filed.


						21

Earnings Call October 28, 2021 Supplemental information Third Quarter

Encompass Health 2 The information contained in this presentation includes certain estimates, projections and other forward-looking information that reflect Encompass Health’s current outlook, views and plans with respect to future events, including the ongoing strategic review and its impact on the business model, outlook and guidance, the COVID-19 pandemic and its effects, legislative and regulatory developments, strategy, capital expenditures, acquisition and other development activities, cyber security, dividend strategies, repurchases of securities, effective tax rates, financial performance, financial assumptions, business model, balance sheet and cash flow plans, market share, development of new information tools and models, and shareholder value-enhancing transactions. These estimates, projections and other forward-looking information are based on assumptions the Company believes, as of the date hereof, are reasonable. Inevitably, there will be differences between such estimates and actual events or results, and those differences may be material. There can be no assurance any estimates, projections or forward-looking information will be realized. All such estimates, projections and forward-looking information speak only as of the date hereof. Encompass Health undertakes no duty to publicly update or revise the information contained herein. You are cautioned not to place undue reliance on the estimates, projections and other forward-looking information in this presentation as they are based on current expectations and general assumptions and are subject to various risks, uncertainties and other factors, including those set forth in the earnings release attached as Exhibit 99.1 to the Company’s Form 8-K dated October 27, 2021 (the “Q3 Earnings Release Form 8-K”), the Form 10-K for the year ended December 31, 2020, the Form 10-Q for the quarters ended March 31, 2021, June 30, 2021, and September 30, 2021, when filed, and in other documents Encompass Health previously filed with the SEC, many of which are beyond Encompass Health’s control, that may cause actual events or results to differ materially from the views, beliefs and estimates expressed herein. Note regarding presentation of non-GAAP financial measures The following presentation includes certain “non-GAAP financial measures” as defined in Regulation G under the Securities Exchange Act of 1934, including Adjusted EBITDA, leverage ratios, adjusted earnings per share, and adjusted free cash flow. Schedules are attached that reconcile the non-GAAP financial measures included in the following presentation to the most directly comparable financial measures calculated and presented in accordance with Generally Accepted Accounting Principles in the United States. The Q3 Earnings Release Form 8-K, to which the following presentation is attached as Exhibit 99.2, provides further explanation and disclosure regarding Encompass Health’s use of non-GAAP financial measures and should be read in conjunction with this supplemental information. Forward-looking statements

Encompass Health 3 Key takeaways ........................................................................................................................................................ 4 Q3 2021 summary ................................................................................................................................................... 5-6 Inpatient rehabilitation segment ........................................................................................................................ 7-9 Home health & hospice segment ........................................................................................................................ 10-13 Consolidated Adjusted EBITDA ............................................................................................................................ 14 Earnings per share ................................................................................................................................................. 15-16 Adjusted free cash flow ........................................................................................................................................ 17 Guidance and considerations for 2021 ............................................................................................................... 18-19 Adjusted free cash flow assumptions ................................................................................................................. 20 Uses of free cash flow ........................................................................................................................................... 21 Appendix Map of locations ..................................................................................................................................................... 23 Expansion activity .................................................................................................................................................. 24 Clinical collaboration ............................................................................................................................................ 25 Pre-payment claims denials - inpatient rehabilitation segment ................................................................... 26 Debt maturity profile and schedule ................................................................................................................... 27-28 New-store/same-store growth ............................................................................................................................. 29-31 Payment sources (percent of revenues) ............................................................................................................ 32 Inpatient rehabilitation operational metrics .................................................................................................... 33 Home health & hospice operational metrics .................................................................................................... 34 Share information .................................................................................................................................................. 35 Segment operating results .................................................................................................................................... 36-38 Reconciliations to GAAP ........................................................................................................................................ 39-47 End notes ................................................................................................................................................................. 48-49 Table of contents

Encompass Health 4 Key takeaways u Consolidated revenue grew 9.4% and Adjusted EBITDA grew 6.7% Ÿ Strong revenue and Adjusted EBITDA growth in inpatient rehabilitation business over Q3 2020 and Q3 2019 ü Discharge growth of 8.7% ü Pricing continues to reflect elevated acuity Ÿ Home health and hospice volumes and labor costs negatively impacted by COVID-19 surge ü Home health admissions declined 0.9% ü Cost per visit increased 9.3% u 2021 guidance is being revised to reflect Q3 results and current operating trends Ÿ Revised guidance reflects anticipation of continuing volume challenges in home health and hospice and continued higher labor costs in both segments. u Current expectations of ongoing strategic alternatives review for home health and hospice business Ÿ The Company announced yesterday that it expects to effect the partial or full separation of its home health and hospice business into an independent public company via a carve-out IPO, spin-off, or split-off. Ÿ The Company is targeting such a transaction in the first half of 2022 and expects to announce a more precise timing and the form of the separation transaction in connection with its fourth quarter earnings release. Ÿ While there can be no assurance that a transaction of this nature will be consummated, the Company has made significant progress on the various tasks necessary to complete a separation transaction and will further its state of readiness over the balance of this year.

Encompass Health 5 Q3 2021 summary Q3 9 Months ($millions) 2021 2020 %  2021 2020 %  Encompass Health Consolidated Net operating revenues $ 1,284.8 $ 1,173.9 9.4 % $ 3,802.9 $ 3,430.0 10.9 % Adjusted EBITDA $ 245.6 $ 230.2 6.7 % $ 775.3 $ 620.4 25.0 % Adjusted EPS $ 1.03 $ 0.78 32.1 % $ 3.26 $ 1.96 66.3 % Adjusted free cash flow $ 124.1 $ 124.1 — % $ 437.1 $ 366.9 19.1 % Inpatient Rehabilitation Segment Net operating revenues $ 1,010.9 $ 899.4 12.4 % $ 2,972.4 $ 2,633.1 12.9 % Adjusted EBITDA $ 231.6 $ 209.2 10.7 % $ 720.5 $ 605.0 19.1 % Home Health and Hospice Segment Net operating revenues $ 273.9 $ 274.5 (0.2) % $ 830.5 $ 796.9 4.2 % Adjusted EBITDA $ 46.4 $ 51.8 (10.4) % $ 158.9 $ 107.8 47.4 % Reconciliations to GAAP provided on pages 39-47

Encompass Health 6 Q3 2021 summary (continued) u IRF expansion activity - Opened 4 inpatient rehabilitation hospitals in Q3, 8 opened YTD (see page 24) Ÿ Q3 inpatient rehabilitation hospital openings ü Shreveport, LA - 40 beds ü Waco, TX - 40 beds ü Greenville, SC - 40 beds ü Pensacola, FL - 40 beds Ÿ Announced plans to build three inpatient rehabilitation hospitals in: ü Palm Beach Gardens, FL - 50 beds ü Fitchburg, WI - 40 beds ü Lake Worth, FL - 50 beds Ÿ Added 33 beds to existing hospitals (89 beds added year to date) u Balance sheet - See debt schedule and maturity profile on pages 27-28 Ÿ Net leverage ratio of 3.1x at quarter end u Shareholder and other distributions Ÿ Paid quarterly cash dividend of $0.28 per share in July 2021 Ÿ Declared a $0.28 per share quarterly cash dividend in July 2021 (paid in October 2021) Ÿ Declared a $0.28 per share quarterly cash dividend in October 2021 (to be paid in January 2022)

Encompass Health 7 Inpatient rehabilitation segment Revenue growth of 12.4% u Inpatient revenue growth resulted from increased volumes and pricing Ÿ Total discharge growth of 8.7%, inclusive of same-store growth of 6.7% Ÿ Growth in net patient revenue per discharge of 2.4% primarily resulted from an increase in reimbursement rates and higher patient acuity u The increase in outpatient and other revenue included an increase of $11.3 million in provider tax revenues ($18.2 million in Q3 2021 vs. $6.9 million in Q3 2020), offset by an increase of $9.3 million in provider tax expenses included in other operating expenses ($17.0 million in Q3 2021 vs. $7.7 million in Q3 2020). Adjusted EBITDA increased 10.7% u Adjusted EBITDA growth primarily resulted from revenue growth u Salaries and benefits as a % of revenue increased by 30 bps, primarily due to: Ÿ Higher sign-on and shift bonuses plus contract labor to meet increased patient volumes Ÿ Pre-opening and ramp-up costs associated with new stores Ÿ These items were partially offset by a reduction in employees per occupied bed (“EPOB”) u Other operating expenses as a % of revenue increased 40 bps, due to the increase in provider tax expense u Includes $6.5 million of pre-opening and new-store ramp-up costs in Q3 2021 ($1.9 million in Q3 2020) See operating metrics on page 33.

Encompass Health 8 Inpatient rehabilitation segment - revenue Q3 Q3 Favorable/ ($millions) 2021 2020 (Unfavorable) Net operating revenues: Inpatient $ 983.7 $ 883.2 11.4% Outpatient and other 27.2 16.2 67.9% Total segment revenue $ 1,010.9 $ 899.4 12.4% (Actual Amounts) Discharges 49,983 45,962 8.7% Same-store discharge growth 6.7% Net patient revenue per discharge $ 19,681 $ 19,216 2.4% Revenue reserves related to bad debt as a percent of revenue 2.0 % 1.4 % 60 basis points Revenue reserves related to bad debt as a percent of revenue increased 60 bps to 2.0%, primarily due to the impact of slower claims processing by managed care payors.

Encompass Health 9 Inpatient rehabilitation segment - Adjusted EBITDA Q3 % of Revenue Q3 % of Revenue($millions) 2021 2020 Net operating revenues $ 1,010.9 $ 899.4 Operating expenses: Salaries and benefits (537.1) 53.1 % (475.0) 52.8 % Other operating expenses(a) (156.2) 15.5 % (135.5) 15.1 % Supplies (46.8) 4.6 % (45.3) 5.0 % Occupancy costs (14.4) 1.4 % (15.3) 1.7 % Hospital operating expenses (217.4) 21.5 % (196.1) 21.8 % Other income(b) 0.7 2.1 Equity in nonconsolidated affiliates 0.8 0.9 Noncontrolling interests (26.3) (22.1) Segment Adjusted EBITDA $ 231.6 $ 209.2 Percent change 10.7 % In arriving at Adjusted EBITDA, the following were excluded: (a) (Gain) loss on disposal or impairment of assets $ (5.0) $ 7.5 (b) Change in fair market value of equity securities $ 0.3 $ (0.4) Reconciliations to GAAP provided on pages 39-47 Salaries and benefits, supplies, and occupancy costs as a percent of revenues benefited from the increase in provider tax revenues. Other operating expenses as a percent of revenue was negatively impacted by the increase in provider tax expenses, discussed on slide 7.

Encompass Health 10 Home health and hospice segment Revenue decreased 0.2% u Revenue decrease resulted from a reduction in episodic admissions largely offset by the continued growth in non-episodic admissions, primarily due to our new contract with United Healthcare. u Staffing constraints, continued lower occupancy levels at senior living facilities, and limited elective procedures contributed to the volume decline. Ÿ We lost approximately 2,500 admissions due to staffing constraints ü Staffing constraints resulted primarily from quarantined employees and industry-wide nursing shortages. ü The number of quarantined field employees increased in the third quarter. After averaging 30 in Q2, quarantined employees peaked at 179 in August before declining to 155 in September. Ÿ Episodic admissions of patients residing in senior living facilities declined by ~1,100 compared to Q3 2020 Ÿ Episodic admissions of patients receiving elective procedures in acute care hospitals declined by ~400 compared to Q3 2020 u Revenue per episode increased 0.2%, less than expected, due to the mix between early and late payment periods resulting from the decline in episodic admissions during the quarter. u Growth in hospice revenue resulted from: Ÿ Acquisition of assets from Frontier Home Health and Hospice in June 2021 Ÿ Increased reimbursement rates Ÿ Increased average length of stay Ÿ Offset by a decline in volumes

Encompass Health 11 Home health and hospice segment (continued) Adjusted EBITDA decreased 10.4% u Adjusted EBITDA decreased primarily due to the higher costs of services related to industry-wide staffing challenges Ÿ Cost per visit increased due to lower clinician productivity associated with recent hires, market rate increases for nurses, and increased contract labor. Demand for home healthcare continues to rise u We continue to experience year-over-year growth in patient referrals Ÿ Total home health patient referrals grew 12.3% YTD and 7.3% in Q3 2021 vs. Q3 2020 Ÿ Added over 3,000 new referral sources in Q3 2021 Improving trends in October u Average home health admissions per day are up by 14 (~4%) in October 2021 compared to September 2021. u Number of quarantined field employees averaged 179 in August, 155 in September and 109 in October. u Staffing constraint mitigation strategies include offering more flexible work schedules, increasing our hiring incentives, and implementing market rate adjustments. See operating metrics on page 34.

Encompass Health 12 Home health and hospice segment - revenue Q3 Q3 Favorable/ ($millions) 2021 2020 (Unfavorable) Net operating revenues: Home health revenue $ 219.9 $ 224.8 (2.2) % Hospice revenue 50.6 48.0 5.4 % Total segment revenue $ 270.5 $ 272.8 (0.8) % Home Health Metrics (Actual Amounts) Episodic admissions 40,215 42,476 (5.3) % Same-store episodic admissions growth (5.4) % Episodes 66,435 68,652 (3.2) % Same-store episode growth (3.4) % Revenue per episode $ 2,923 $ 2,909 0.5 % Q3 Q3 Favorable/ ($millions) 2021 2020 (Unfavorable) Net operating revenues: Home health revenue $ 221.1 $ 223.3 (1.0) % Hospice revenue 52.8 51.2 3.1 % Total segment revenue $ 273.9 $ 274.5 (0.2) % Home Health Starts of care: Episodic admissions 37,577 40,765 (7.8) % Same-store episodic admissions growth (9.7) % Episodic recertifications 27,742 29,830 (7.0) % Total episodic starts of care 65,319 70,595 (7.5) % Total admissions 48,412 48,838 (0.9) % Same-store total admissions growth (2.7) % Total recertifications 32,942 33,786 (2.5) % Total starts of care 81,354 82,624 (1.5) % Revenue per episode $ 2,916 $ 2,910 0.2 % Hospice Admissions: Same store 2,884 3,354 (14.0) % New store 378 — 11.3 % Total admissions 3,262 3,354 (2.7) %

Encompass Health 13 Q3 % of Revenue Q3 % of Revenue($millions) 2021 2020 Net operating revenues $ 273.9 $ 274.5 Cost of services (124.0) 45.3 % (121.8) 44.4 % Support and overhead costs (103.2) 37.7 % (100.7) 36.7 % Operating expenses(a) (227.2) 82.9 % (222.5) 81.1 % Equity in net income of nonconsolidated affiliates 0.1 0.1 Noncontrolling interests (0.4) (0.3) Segment Adjusted EBITDA $ 46.4 $ 51.8 Percent change (10.4) % In arriving at Adjusted EBITDA, the following were excluded: (a) Gain on disposal of assets $ (0.2) $ — Home health and hospice segment - Adjusted EBITDA Reconciliations to GAAP provided on pages 39-47

Encompass Health 14 Consolidated Adjusted EBITDA ($millions) Q3 2021 % of Consolidated Revenue Q3 2020 % of Consolidated Revenue Inpatient rehabilitation segment Adjusted EBITDA $ 231.6 $ 209.2 Home health and hospice segment Adjusted EBITDA 46.4 51.8 General and administrative expenses* (32.4) 2.5% (30.8) 2.6% Consolidated Adjusted EBITDA $ 245.6 $ 230.2 Percentage change 6.7 % Reconciliations to GAAP provided on pages 39-47 Consolidated Adjusted EBITDA for the quarter of $245.6 million u General and administrative expenses decreased as a percent of consolidated revenue due to the increased revenue base year-over-year. * General and administrative expenses in the above table exclude stock compensation of $6.9 million and $8.3 million for Q3 2021 and Q3 2020, respectively, as well as $4.6 million in costs associated with the strategic alternatives review of our home health and hospice business for Q3 2021.

Encompass Health 15 Earnings per share - as reported Q3 9 Months (In Millions, Except Per Share Data) 2021 2020 2021 2020 Adjusted EBITDA $ 245.6 $ 230.2 $ 775.3 $ 620.4 Depreciation and amortization (64.9) (61.2) (190.8) (180.7) Interest expense and amortization of debt discounts and fees (39.9) (49.0) (124.5) (138.0) Stock-based compensation expense (6.9) (8.3) (21.7) (25.3) Gain (loss) on disposal or impairment of assets 5.2 (7.5) 2.4 (10.6) 139.1 104.2 440.7 265.8 Certain items not indicative of ongoing operating performance: Loss on early extinguishment of debt(1) — — (1.0) — Costs associated with the strategic alternatives review (4.6) — (9.6) — Costs associated with the Frontier acquisition — — (1.3) — Gain on consolidation of former equity method location(2) — — — 2.2 Change in fair market value of equity securities (0.3) 0.4 0.3 0.3 Government, class action, and related settlements(3) — — — (2.8) Payroll taxes on SARs exercise(4) — — — (1.5) Pre-tax income 134.2 104.6 429.1 264.0 Income tax expense (34.1) (26.9) (108.1) (65.8) Income from continuing operations* $ 100.1 $ 77.7 $ 321.0 $ 198.2 Diluted shares (see page 35) 100.2 99.9 100.1 99.7 Diluted earnings per share* $ 1.00 $ 0.78 $ 3.20 $ 1.99 u The increase in EPS in the third quarter of 2021 and the year-to-date period primarily resulted from increased Adjusted EBITDA. * Earnings per share are determined using income from continuing operations attributable to Encompass Health. Refer to pages 48-49 for end notes.

Encompass Health 16 Adjusted earnings per share(5) * Adjusted EPS may not sum due to rounding. See complete calculations of adjusted earnings per share on pages 44-47. Refer to pages 48-49 for end notes. Q3 9 Months 2021 2020 2021 2020 Earnings per share, as reported $ 1.00 $ 0.78 $ 3.20 $ 1.99 Adjustments, net of tax: Government, class action, and related settlements(3) — — — 0.02 Costs associated with the strategic alternatives review 0.03 — 0.07 — Costs associated with the Frontier acquisition — — 0.01 — Income tax adjustments — — (0.04) (0.05) Loss on early extinguishment of debt(1) — — 0.01 — Gain on consolidation of former equity method location(2) — — — (0.02) Payroll taxes on SARs exercise(4) — — — 0.01 Adjusted earnings per share* $ 1.03 $ 0.78 $ 3.26 $ 1.96 u Adjusted earnings per share removes from the GAAP earnings per share calculation the impact of items the Company believes are non-indicative of its ongoing operating performance.

Encompass Health 17 $366.9 $154.9 ($51.5) $14.3 ($69.1) $21.6 $437.1 Adjusted Free Cash Flow 9 Mos. 2020 Adjusted EBITDA Working capital and other Cash interest payments Cash tax payments, net of refunds Maintenance capital expenditures Adjusted Free Cash Flow 9 Mos. 2021 2021 Adjusted free cash flow(6) Reconciliations to GAAP provided on pages 39-47 Refer to pages 48-49 for end notes. u Adjusted free cash flow was higher in the first nine months of 2021 than 2020 primarily due to an increase in Adjusted EBITDA and lower maintenance capital expenditures. u Increased working capital primarily resulted from the timing of payroll accruals related to the award of additional PTO to employees in Q2 2020 and the deferral of payroll taxes resulting from government relief efforts. u Increased cash tax payments in 2021 due to higher year-over-year book income and tax relief in 2020 associated with the CARES Act. ($ in millions)

Encompass Health 18 2021 Full-Year Guidance - Updated as of October 27, 2021 The Company's 2021 guidance assumes the continuation of the current structure of the business for 2021. Refer to pages 48-49 for end notes. Initial Guidance Updated Guidance Updated Guidance Revised Guidance ($ in millions, except per share data) January 26, 2021 April 27, 2021 July 27, 2021 Net Operating Revenue $5,000 to $5,170 $5,060 to $5,230 $5,100 to $5,250 $5,080 to $5,130 Adjusted EBITDA (7) $925 to $955 $1,000 to $1,030 $1,050 to $1,070 $1,025 to $1,045 Adjusted earnings per share from continuing operations attributable to Encompass Health (5) $3.31 to $3.53 $3.94 to $4.16 $4.32 to $4.47 $4.23 to $4.38

Encompass Health 19 Q4 2021 guidance considerations Inpatient Rehabilitation u Estimated Medicare pricing increase of 1.9% u Revenue reserve related to bad debt of 1.8% to 2.0% of net operating revenues u Salaries and benefits per FTE increase of 5% to 6% u Pre-opening and new-store ramp-up costs of $1 million to $3 million Home Health and Hospice u Estimated 1.9% increase in Medicare pricing for home health; estimated 2.0% pricing increase for hospice u Cost per visit estimated to be $82, reflecting continued industry-wide staffing challenges Both Segments u Includes the suspension of sequestration through December 31, 2021 u Continued elevated utilization and costs of personal protective equipment and testing

Encompass Health 20 Adjusted free cash flow(6) assumptions Reconciliations to GAAP provided on pages 39-47; Refer to pages 48-49 for end notes. Certain cash flow items (millions) 9 Months 2021 Actuals 2021 Assumptions 2020 Actuals Cash interest payments (net of amortization of debt discounts and fees) $118.6 $155 to $165 $177.0 Cash payments for income taxes, net of refunds $99.3 $125 to $140 $32.9 Working capital and other $34.4 $100 to $120 ($84.4) Maintenance CAPEX $85.9 $140 to $150 $154.9 Adjusted free cash flow $437.1 $450 to $525 $579.9 u Higher cash payments for taxes expected in 2021 due to: Ÿ higher expected book income Ÿ tax relief in 2020 under the CARES Act Ÿ lower stock-based compensation due to the final payout of the Home Health Holdings SARs in Q1 2020(4) u Increased working capital expected in 2021 primarily due to the timing of payroll accruals related to the award of additional PTO to employees in 2020 and the deferral of payroll taxes resulting from government relief efforts u Lower maintenance capital expenditures u Lower average interest rate expected in 2021 due to the redemption of the 5.75% Senior Notes due 2024 in Q4 2020 and the redemption of $200 million of 5.125% Senior Notes due 2023 in Q2 2021

Encompass Health 21 Uses of free cash flow ($millions) 9 Months 2021 Actuals 2021 Assumptions 2020 Actuals Growth in core business IRF bed expansions $33.2 $50 to $60 $44.8 New IRFs - De novos 198.4 300 to 320 173.0 - Acquisitions 1.1 opportunistic — - Replacement IRFs and other 35.1 40 to 50 35.5 Home health and hospice acquisitions 97.7 ~100 1.1 $365.5 $490 to $530 $254.4 Debt reduction Debt redemptions (borrowings), net $81.0 opportunistic ($226.3) Shareholder and other distributions Cash dividends on common stock 84.7 ~$112 111.9 Purchase of Home Health Holdings rollover shares and exercise of SARs(4) — N/A 262.9 Common stock repurchases — opportunistic 6.1 ~$198 million authorization remaining as of September 30, 2021(8) See the debt schedule on page 28. Refer to pages 48-49 for end notes. Quarterly cash dividend currently set at $0.28 per common share

Appendix

Encompass Health 23 Inpatient rehabilitation - 9/30/21 144 IRFs (53 are joint ventures) 35 States and Puerto Rico ~32,800 Employees 24 % of licensed beds† 31 % of Medicare patients served† Key statistics - trailing 4 quarters ~193,200 Inpatient discharges ~$3.9 Billion in revenue * Excluding markets that have home health licensure barriers ** Future IRFs - Previously announced under development as of October 27, 2021 † Based on 2019 and 2020 data Note: One of the 249 home health locations is nonconsolidated. This location is accounted for using the equity method of accounting. Portfolio as of 9/30/21 Inpatient rehabilitation hospitals (“IRFs”) Home health locations Hospice locations 23 Future IRFs** 42 States and Puerto Rico ~43,800 employees Encompass Health a leading provider of inpatient rehabilitation and home-based care 93 of EHC’s IRFs have an EHC home health location within the service area.* Largest owner and operator of IRFs 4th Largest provider of Medicare-certified skilled home health services Home health and hospice - 9/30/21 249 Home health locations 95 Hospice locations 34 States ~11,000 Employees Key statistics - trailing 4 quarters ~158,300 Home health episodic admissions ~13,200 Hospice admissions ~$1.1 Billion in revenue

Encompass Health 24 Inpatient Rehabilitation Facilities Under Development Expected Operations date Joint venture? # of New Beds 2021 2022 2023 De novo IRFs: 1 Libertyville, IL Q1 2022 — 60 — 2 St. Augustine, FL Q1 2022 — 40 — 3 Shiloh, IL Q1 2022 Yes — 40 — 4 Lakeland, FL Q2 2022 — 50 — 5 Cape Coral, FL Q2 2022 — 40 — 6 Jacksonville, FL Q2 2022 — 50 — 7 Grand Forks, ND Q2 2022 Yes — 40 — 8 Moline, IL Q3 2022 Yes — 40 — 9 Naples, FL Q3 2022 — 50 — 10 Eau Claire, WI Q4 2022 Yes — 36 — 11 Clermont, FL TBD — — 50 12 Owasso, OK TBD Yes — — 40 13 Bowie, MD TBD — — 60 14 Knoxville, TN TBD Yes — — 73 15 Prosper, TX TBD — — 40 16 Columbus, GA TBD Yes — — 40 17 Fitchburg, WI TBD — — 40 18 Kissimmee, FL TBD — — 50 19 Fort Mill, SC TBD — — 39 20 Louisville, KY TBD Yes — — 40 21 Palm Beach Gardens, FL* TBD — — — 22 Atlanta, GA* TBD Yes — — — 23 Lake Worth, FL* TBD — — — Opened YTD** 350 Bed expansions, net*** ~130 ~100 ~100 ~480 ~550 ~570 Expansion activity * Scheduled to open in 2024 **Henry County, GA (Stockbridge) opened in October 2021 *** Net bed expansions in each year may change due to the timing of certain regulatory approvals and/or construction delays. For 2021 and 2022, the currently expected range for bed expansions is 100 to 150. 2021 YTD expansion activity highlights u Opened 8 inpatient rehabilitation hospitals Ÿ 40-bed hospital in San Angelo, TX Ÿ 50-bed hospital in North Tampa, FL Ÿ 50-bed hospital in Cumming, GA Ÿ 40-bed hospital in Greenville, SC Ÿ 40-bed hospital in Shreveport, LA Ÿ 40-bed hospital in Waco, TX Ÿ 40-bed hospital in Pensacola, FL Ÿ 50-bed hospital in Henry County, GA (Stockbridge) u Added 89 beds to existing hospitals u Announced plans to build 14 inpatient rehabilitation hospitals u Closed the Frontier acquisition Ÿ 9 home health and 11 hospice locations Ÿ 3 new states: Alaska, Washington and Montana IRF development projects announced and underway Home Health and Hospice Locations # of Locations December 31, 2020 323 Acquisitions 20 Opening of new locations 2 Merging of locations (1) September 30, 2021 344 23

Encompass Health 25 * Overlap markets have an Encompass Health IRF and an Encompass Health home health location within an approximate 30-mile radius, excluding markets that have home health licensure barriers. Overlap markets are open for 12 months before inclusion in the clinical collaboration rate. The Company continues to improve the patient experience and outcomes through integrated care delivery. Inpatient rehabilitation–home health clinical collaboration (all payors) overlap markets* EHC Home Health Non-EHC Home Health Encompass Health IRF discharges to: Overlap Markets* Clinical Collaboration Rate 17.260 u Clinical collaboration objectives: Ÿ Improve patient experience and outcomes Ÿ Reduce total cost of care across a post-acute episode 72 76 81 89 89 93 25.4% 29.5% 34.0% 35.6% 33.2% 31.9% 2016 2017 2018 2019 2020 Q3 YTD 2021 40,637 42,950 41,858 44,479 51,287 13,800 17,947 21,547 24,560 25,444 43,028 20,173 uThe clinical collaboration rate has decreased primarily due to Medicare Advantage increasing as a percent of the total patient mix and home health staffing constraints in certain overlap markets.

Encompass Health 26 Pre-payment claims denials - inpatient rehabilitation segment Impact to Income Statement Period New Denials Collections of Previously Denied Claims Revenue Reserve for New Denials Update of Reserve for Prior Denials (In Millions) Q3 2021 $(0.5) $(9.7) $— $— Q2 2021 0.1 (6.3) — — Q1 2021 (0.2) (5.2) — — Q4 2020 (0.4) (7.2) — 4.5 Q3 2020 (0.6) (6.3) — — Q2 2020 (1.5) (3.5) — — Q1 2020 4.2 (5.0) 1.3 — Q4 2019 3.8 (4.6) 1.1 — Q3 2019 11.3 (6.1) 3.4 — Q2 2019 3.5 (1.7) 1.1 — Q1 2019 1.6 (2.5) 0.5 — Q4 2018 4.6 (3.2) 1.4 — Q3 2018 0.7 (1.3) 0.2 — Impact to Balance Sheet Sep. 30, 2021 Dec. 31, 2020 Dec. 31, 2019 (In Millions) Pre-payment claims denials $ 83.7 $ 122.8 $ 155.3 Recorded reserves (28.2) (41.3) (46.6) Net accounts receivable from pre-payment claims denials $ 55.5 $ 81.5 $ 108.7 Background • For several years prior to 2018, under programs designated as “widespread probes,” certain Medicare Administrative Contractors (“MACs”) conducted pre-payment claim reviews and denied payment for certain diagnosis codes. • Since 2018, CMS has replaced the “widespread probes” with the Targeted Probe and Educate (“TPE”) initiative.* • Encompass Health appeals most denials. – MACs identify medical documentation issues as a leading basis for denials. – Encompass Health’s investment in clinical information systems and its medical services department has further improved its documentation and reduced technical denials. • By statute, ALJ decisions are due within 90 days of a request for hearing, but appeals are taking years. HHS has implemented rule changes to address the backlog of appeals, but their effect is uncertain. • In November 2018, a federal court ordered HHS to reduce the backlog in the following increments: a 19% reduction by the end of FY 2019; a 49% reduction by the end of FY 2020; a 75% reduction by the end of FY 2021; and elimination of the backlog by the end of FY 2022. • After years of delay in processing appeals, ALJs recently increased the frequency of hearings and the number of claims set at each hearing. Notwithstanding the recent acceleration, Encompass Health still has over 4,700 claims in the backlog. • Effective March 2020, CMS suspended most Medicare fee-for- service medical reviews during the public health emergency, including TPE and current post-payment reviews, allowing reviews for potential fraud. CMS authorized its contractors to resume reviews as of August 2020. Encompass Health reserves pre-payment claim denials as a reduction of net operating revenues upon notice from a MAC a claim is under review. * For more information regarding TPE, see https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/ Medicare-FFS-Compliance-Programs/Medical-Review/Targeted-Probe-and-EducateTPE.html

Encompass Health 27 * This chart does not include ~$416 of finance lease obligations or ~$50 of other notes payable. See the debt schedule on page 28. Debt maturity profile - face value 2021 2022 2023 2024 2024 2025 2026 2027 2028 2029 2030 2031 $350 Senior Notes 5.75% $100 Senior Notes 5.125% ($ in millions) Revolver capacity $242 Term Loans No significant debt maturities prior to 2023 Callable $800 Senior Notes 4.75% $800 Senior Notes 4.5% Revolver As of September 30, 2021*) $872 Available $90 Drawn + $38 reserved for LCs Callable Callable beginning February 2025Callable beginning February 2023 $400 Senior Notes 4.625% Callable beginning April 2026

Encompass Health 28 Debt schedule Change in September 30, December 31, Debt vs. ($millions) 2021 2020 YE 2020 Advances under $1 billion revolving credit facility, November 2024 - LIBOR +150bps $ 90.0 $ — $ 90.0 Term loan facility, November 2024 - LIBOR +150bps 241.8 251.6 (9.8) Bonds Payable: 5.125% Senior Notes due 2023(1) 99.6 298.1 (198.5) 5.75% Senior Notes due 2025 346.8 346.3 0.5 4.50% Senior Notes due 2028 786.4 785.0 1.4 4.75% Senior Notes due 2030 784.3 783.2 1.1 4.625% Senior Notes due 2031 393.6 393.2 0.4 Other notes payable 49.7 39.8 9.9 Finance lease obligations 415.7 391.7 24.0 Long-term debt $ 3,207.9 $ 3,288.9 $ (81.0) Debt to Adjusted EBITDA 3.2 x 3.8 x Leverage net of cash on balance sheet 3.1 x 3.6 x Reconciliations to GAAP provided on pages 39-47; Refer to pages 48-49 for end notes.

Encompass Health 29 * Includes consolidated inpatient rehabilitation hospitals classified as same store during each period Refer to pages 48-49 for end notes. Q4 2018 Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 -10.0 0.0 10.0 20.0 New-store/same-store growth Inpatient Rehabilitation Yuma, AZ (51 beds)(9) Boise, ID (40 beds) Katy, TX (40 beds) North Tampa, FL (50 beds) Cumming, GA (50 beds) Shreveport, LA (40 beds) Waco, TX (40 beds) Greenville, SC (40 beds) Pensacola, FL (40 beds) Winston-Salem, NC (68 beds) Lubbock, TX (40 beds) Discharges Q4 2018 Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 New store 1.7% 1.3% 1.5% 2.4% 2.0% 2.3% 2.1% 1.3% 0.9% 1.0% 1.8% 2.0% Same store* 1.9% (0.2)% 2.2% 3.1% 3.2% 2.4% (12.8)% (2.8)% (3.8)% (2.2)% 16.9% 6.7% Total by quarter 3.6% 1.1% 3.7% 5.5% 5.2% 4.7% (10.7)% (1.5)% (2.9)% (1.2)% 18.7% 8.7% Total by year 4.6% 3.9% (2.6)% Same-store year* 2.8% 1.8% (4.4)% Same-store year UDS(10) 1.1% 1.3% (3.2)% Murrieta, CA (50 beds) Sioux Falls, SD (40 beds) Coralville, IA (40 beds) Beginning in mid-March 2020, volume growth was impacted by COVID-19. Toledo, OH (40 beds) San Angelo, TX (40 beds)

Encompass Health 30 Q4 2018 Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 -20.0 -10.0 0.0 10.0 20.0 30.0 New-store/same-store growth Home Health Episodic admissions Q4 2018 Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 New store 5.3% 5.7% 2.9% 13.0% 12.3% 11.7% 9.4% 1.3% 1.5% 0.1% 0.9% 1.9% Same store* 5.4% 6.4% 8.3% 9.7% 6.6% 0.2% (17.3)% (4.6)% (3.8)% (5.4)% 12.9% (9.7)% Total by quarter 10.7% 12.1% 11.2% 22.7% 18.9% 11.9% (7.9)% (3.3)% (2.3)% (5.3)% 13.8% (7.8)% Total by year 10.0% 16.3% (0.5)% Same-store year* 5.6% 7.7% (6.1)% u In 2018, the Company acquired or opened 23 home health locations. u In 2019, the Company acquired or opened 27 home health locations. u In 2020, the Company acquired or opened two home health locations and consolidated one former equity method location(2). u In 2021, the Company acquired nine home health locations and merged one location. Acquired Frontier Home Health & Hospice (9 home health locations in 5 states) in June 2021 Acquired Alacare Home Health & Hospice (23 home health locations in Alabama) in July 2019 * Includes consolidated home health agencies classified as same-store during each period Refer to pages 48-49 for end notes. Beginning in mid-March 2020, volume growth was impacted by COVID-19.

Encompass Health 31 Q4 2018 Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 -10.0 0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 * Includes consolidated hospice agencies classified as same-store during each period New-store/same-store growth Hospice Admissions Q4 2018 Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 New store 41.2% 35.5% 15.7% 34.6% 31.1% 30.9% 30.6% 0.5% 0.7% 0.1% 5.3% 11.3% Same store* 8.6% 13.7% 13.6% 5.8% 10.1% (5.3)% 6.7% 15.8% 16.1% 11.4% (1.9)% (14.0)% Total by quarter 49.8% 49.2% 29.3% 40.4% 41.2% 25.6% 37.3% 16.3% 16.8% 11.5% 3.4% (2.7)% Total by year 53.5% 39.8% 23.2% Same-store year* 24.6% 12.2% 8.1% u In 2018, the Company acquired or opened 22 hospice locations. u In 2019, the Company acquired or opened 25 hospice locations. u In 2020, the Company opened one hospice location. u In 2021, the Company acquired or opened 13 hospice locations. Acquired Frontier Home Health & Hospice (11 hospice locations in 5 states) in June 2021 Acquired Alacare Home Health & Hospice (23 hospice locations in Alabama) in July 2019

Encompass Health 32 Payment sources (percent of revenues) Inpatient Rehabilitation Segment Home Health and Hospice Segment Consolidated Q3 Q3 Q3 9 Months Full Year 2021 2020 2021 2020 2021 2020 2021 2020 2020 Medicare 64.2 % 65.8 % 81.9 % 83.3 % 68.0 % 69.9 % 68.3 % 69.8 % 70.5 % Medicare Advantage 15.1 % 15.7 % 10.4 % 10.8 % 14.1 % 14.5 % 14.5 % 14.8 % 14.2 % Managed care 12.2 % 10.7 % 6.2 % 4.5 % 10.9 % 9.2 % 10.5 % 9.0 % 9.0 % Medicaid 4.1 % 4.3 % 1.4 % 1.2 % 3.5 % 3.6 % 3.5 % 3.4 % 3.4 % Other third-party payors 1.0 % 1.2 % — % — % 0.8 % 0.9 % 0.9 % 0.9 % 0.9 % Workers’ compensation 0.6 % 0.5 % — % 0.1 % 0.5 % 0.4 % 0.4 % 0.5 % 0.5 % Patients 0.5 % 0.6 % — % 0.1 % 0.4 % 0.5 % 0.4 % 0.5 % 0.4 % Other income 2.3 % 1.2 % 0.1 % — % 1.8 % 1.0 % 1.5 % 1.1 % 1.1 % Total 100.0 % 100.0 % 100.0 % 100.0 % 100.0 % 100.0 % 100.0 % 100.0 % 100.0 %

Encompass Health 33 Inpatient rehabilitation operational metrics Q3 Q2 Q1 Q4 Q3 Q2 Q1 Full Year 2021 2021 2021 2020 2020 2020 2020 2020 (In Millions) Net patient revenue-inpatient $ 983.7 $ 976.9 $ 942.3 $ 914.9 $ 883.2 $ 808.0 $ 890.0 $ 3,496.1 Net patient revenue-outpatient and other revenues 27.2 24.7 17.6 18.2 16.2 16.5 19.2 70.1 Net operating revenues $ 1,010.9 $ 1,001.6 $ 959.9 $ 933.1 $ 899.4 $ 824.5 $ 909.2 $ 3,566.2 (Actual Amounts) Discharges(11) 49,983 49,492 47,187 46,503 45,962 41,682 47,750 181,897 Net patient revenue per discharge $ 19,681 $ 19,739 $ 19,969 $ 19,674 $ 19,216 $ 19,385 $ 18,639 $ 19,220 Outpatient visits 38,904 44,020 40,194 48,786 51,968 15,760 69,743 186,257 Average length of stay 12.8 12.7 13.0 12.9 13.0 13.2 12.7 12.9 Occupancy % 70.6 % 71.1 % 71.4 % 68.7 % 68.8 % 64.5 % 71.3 % 67.7 % # of licensed beds 9,846 9,701 9,560 9,505 9,437 9,401 9,322 9,505 Occupied beds 6,951 6,897 6,826 6,530 6,493 6,064 6,647 6,435 Full-time equivalents (FTEs)(12) 23,054 22,535 22,383 22,383 22,147 20,809 22,318 21,915 Contract labor 383 318 221 192 176 116 161 161 Total FTE and contract labor 23,437 22,853 22,604 22,575 22,323 20,925 22,479 22,076 EPOB(13) 3.37 3.31 3.31 3.46 3.44 3.45 3.38 3.43 Refer to pages 48-49 for end notes.

Encompass Health 34 Home health and hospice operational metrics Q3 Q2 Q1 Q4 Q3 Q2 Q1 Full Year 2021 2021 2021 2020 2020 2020 2020 2020 (In Millions) Net home health revenue $ 221.1 $ 232.3 $ 219.9 $ 227.7 $ 223.3 $ 201.8 $ 224.8 $ 877.6 Net hospice revenue 52.8 53.8 50.6 53.6 51.2 47.8 48.0 200.6 Net operating revenues $ 273.9 $ 286.1 $ 270.5 $ 281.3 $ 274.5 $ 249.6 $ 272.8 $ 1,078.2 Home Health: (Actual Amounts) Total admissions(14) 48,412 50,598 50,799 48,533 48,838 44,124 52,754 194,249 Episodic admissions(14) 37,577 39,657 40,215 40,830 40,765 34,841 42,476 158,912 Total recertifications 32,942 33,794 31,902 33,497 33,786 31,952 29,463 128,698 Episodic recertifications 27,742 28,296 28,083 30,064 29,830 28,328 26,553 114,775 Episodes 66,065 67,839 66,435 71,441 68,261 60,154 68,652 268,508 Average revenue per episode $ 2,916 $ 2,968 $ 2,923 $ 2,883 $ 2,910 $ 2,920 $ 2,909 $ 2,905 Episodic visits per episode 15.0 15.6 15.8 15.7 16.4 17.4 16.3 16.4 Total visits 1,213,370 1,297,350 1,239,073 1,281,830 1,300,866 1,250,546 1,306,230 5,139,472 Cost per visit $ 82 $ 76 $ 77 $ 76 $ 75 $ 89 $ 81 $ 80 Hospice: Admissions(15) 3,262 3,298 3,330 3,348 3,354 3,190 2,986 12,878 Patient days 352,691 351,878 334,400 349,989 346,019 336,507 334,545 1,367,060 Average daily census 3,834 3,867 3,716 3,804 3,761 3,698 3,676 3,735 Revenue per day $ 150 $ 153 $ 151 $ 153 $ 148 $ 142 $ 144 $ 147 Refer to pages 48-49 for end notes.

Encompass Health 35 Share information Weighted Average for the Period Q3 9 Months Full Year (In Millions) 2021 2020 2021 2020 2020 2019 2018 Basic shares outstanding 99.0 98.7 99.0 98.5 98.6 98.0 97.9 Restricted stock awards, dilutive stock options, restricted stock units, and common stock warrants 1.2 1.2 1.1 1.2 1.2 1.4 1.9 Diluted shares outstanding 100.2 99.9 100.1 99.7 99.8 99.4 99.8 End of Period Q3 9 Months Full Year (In Millions) 2021 2020 2021 2020 2020 2019 2018 Basic shares outstanding 99.5 99.4 99.5 99.4 99.4 98.6 98.9

Encompass Health 36 Segment operating results Q3 2021 Q3 2020 (In Millions) IRF Home Health and Hospice Reclasses Consolidated IRF Home Health and Hospice Reclasses Consolidated Net operating revenues $ 1,010.9 $ 273.9 $ — $ 1,284.8 $ 899.4 $ 274.5 $ — $ 1,173.9 Operating Expenses: Inpatient Rehabilitation: Salaries and benefits (537.1) — (193.0) (730.1) (475.0) — (189.9) (664.9) Other operating expenses(a) (156.2) — (22.4) (178.6) (135.5) — (20.4) (155.9) Supplies (46.8) — (6.4) (53.2) (45.3) — (7.2) (52.5) Occupancy costs (14.4) — (5.4) (19.8) (15.3) — (5.0) (20.3) Home Health and Hospice: Cost of services (excluding depreciation and amortization) — (124.0) 124.0 — — (121.8) 121.8 — Support and overhead costs — (103.2) 103.2 — — (100.7) 100.7 — (754.5) (227.2) — (981.7) (671.1) (222.5) — (893.6) Other income(b) 0.7 — — 0.7 2.1 — — 2.1 Equity in net income of nonconsolidated affiliates 0.8 0.1 — 0.9 0.9 0.1 — 1.0 Noncontrolling interests (26.3) (0.4) — (26.7) (22.1) (0.3) — (22.4) Segment Adjusted EBITDA $ 231.6 $ 46.4 $ — 278.0 $ 209.2 $ 51.8 $ — 261.0 General and administrative expenses(c)(d) (32.4) (30.8) Adjusted EBITDA $ 245.6 $ 230.2 In arriving at Adjusted EBITDA, the following were excluded: (a) (Gain) loss on disposal or impairment of assets $ (5.0) $ (0.2) $ — $ (5.2) $ 7.5 $ — $ — $ 7.5 (b) Change in fair market value of equity securities $ 0.3 $ — $ — $ 0.3 $ (0.4) $ — $ — $ (0.4) (c) Stock-based compensation $ — $ — $ — $ 6.9 $ — $ — $ — $ 8.3 (d) Costs associated with the strategic alternatives review $ — $ — $ — $ 4.6 $ — $ — $ — $ — Reconciliations to GAAP provided on pages 39-47.

Encompass Health 37 Segment operating results Nine Months Ended September 30, 2021 Nine Months Ended September 30, 2020 (In Millions) IRF Home Health and Hospice Reclasses Consolidated IRF Home Health and Hospice Reclasses Consolidated Net operating revenues $ 2,972.4 $ 830.5 $ — $ 3,802.9 $ 2,633.1 $ 796.9 $ — $ 3,430.0 Operating Expenses: Inpatient Rehabilitation: Salaries and benefits (1,554.9) — (570.6) (2,125.5) (1,408.7) — (585.7) (1,994.4) Other operating expenses(a) (443.7) — (67.1) (510.8) (394.5) — (66.2) (460.7) Supplies (136.1) — (19.0) (155.1) (126.9) — (21.9) (148.8) Occupancy costs (44.5) — (15.7) (60.2) (46.0) — (14.8) (60.8) Home Health and Hospice: Cost of services (excluding depreciation and amortization) — (364.7) 364.7 — — (389.4) 389.4 — Support and overhead costs(b) — (307.7) 307.7 — — (299.2) 299.2 — (2,179.2) (672.4) — (2,851.6) (1,976.1) (688.6) — (2,664.7) Other income(c)(d) 4.5 1.6 — 6.1 3.9 — — 3.9 Equity in net income of nonconsolidated affiliates 2.4 0.5 — 2.9 2.1 0.4 — 2.5 Noncontrolling interests (79.6) (1.3) — (80.9) (58.0) (0.9) — (58.9) Segment Adjusted EBITDA $ 720.5 $ 158.9 $ — 879.4 $ 605.0 $ 107.8 $ — 712.8 General and administrative expenses(e)(f)(g) (104.1) (92.4) Adjusted EBITDA $ 775.3 $ 620.4 In arriving at Adjusted EBITDA, the following were excluded: (a) (Gain) loss on disposal or impairment of assets $ (1.7) $ (0.7) $ — $ (2.4) $ 9.4 $ 1.2 $ — $ 10.6 (b) Payroll taxes on SARs exercise(4) $ — $ — $ — $ — $ — $ 1.5 $ — $ 1.5 (c) Change in fair market value of equity securities $ (0.3) $ — $ — $ (0.3) $ (0.3) $ — $ — $ (0.3) (d) Gain on consolidation of former equity method location(2) $ — $ — $ — $ — $ — $ (2.2) $ — $ (2.2) (e) Stock-based compensation $ — $ — $ — $ 21.7 $ — $ — $ — $ 25.3 (f) Costs associated with the strategic alternatives review $ — $ — $ — $ 9.6 $ — $ — $ — $ — (g) Costs associated with the Frontier acquisition $ — $ — $ — $ 1.3 $ — $ — $ — $ — Reconciliations to GAAP provided on pages 39-47; Refer to pages 48-49 for end notes.

Encompass Health 38 Segment operating results Year Ended December 31, 2020 (In Millions) IRF Home Health and Hospice Reclasses Consolidated Net operating revenues $ 3,566.2 $ 1,078.2 $ — $ 4,644.4 Operating Expenses: Inpatient Rehabilitation: Salaries and benefits (1,903.8) — (776.7) (2,680.5) Other operating expenses(a) (534.7) — (88.1) (622.8) Supplies (171.0) — (29.5) (200.5) Occupancy costs (61.4) — (19.8) (81.2) Home Health and Hospice: Cost of services (excluding depreciation and amortization) — (511.3) 511.3 — Support and overhead costs(b) — (402.8) 402.8 — (2,670.9) (914.1) — (3,585.0) Other income(c)(d) 8.0 — — 8.0 Equity in net income of nonconsolidated affiliates 3.0 0.5 — 3.5 Noncontrolling interests (83.3) (1.3) — (84.6) Segment Adjusted EBITDA $ 823.0 $ 163.3 $ — 986.3 General and administrative expenses(e) (126.0) Adjusted EBITDA $ 860.3 In arriving at Adjusted EBITDA, the following were excluded: (a) Loss on disposal or impairment of assets $ 10.4 $ 1.2 $ — $ 11.6 (b) Payroll taxes on SARs exercise(4) $ — $ 1.5 $ — $ 1.5 (c) Change in fair market value of equity securities $ (0.4) $ — $ — $ (0.4) (d) Gain on consolidation of former equity method location(2) $ — $ (2.2) $ — $ (2.2) (e) Stock-based compensation $ — $ — $ — $ 29.5 Reconciliations to GAAP provided on pages 39-47; Refer to pages 48-49 for end notes.

Encompass Health 39 Reconciliation of net income to Adjusted EBITDA(7) 2021 Q1 Q2 Q3 9 Months (in millions, except per share data) Total Per Share Total Per Share Total Per Share Total Per Share Net Income $ 132.8 $ 142.0 $ 126.7 $ 401.5 Loss from disc ops, net of tax, attributable to Encompass Health — 0.3 0.1 0.4 Net income attributable to noncontrolling interests (25.5) (28.7) (26.7) (80.9) Income from continuing operations attributable to Encompass Health* 107.3 $ 1.07 113.6 $ 1.13 100.1 $ 1.00 321.0 $ 3.20 Provision for income tax expense 34.5 39.5 34.1 108.1 Interest expense and amortization of debt discounts and fees 42.8 41.8 39.9 124.5 Depreciation and amortization 62.5 63.4 64.9 190.8 Loss on early extinguishment of debt(1) — 1.0 — 1.0 (Gain) loss on disposal or impairment of assets (0.1) 2.9 (5.2) (2.4) Stock-based compensation expense 2.8 12.0 6.9 21.7 Costs associated with the strategic alternatives review 0.9 4.1 4.6 9.6 Costs associated with the Frontier acquisition — 1.3 — 1.3 Gain on consolidation of former equity method location(2) — — — — Change in fair market value of equity securities 0.1 (0.7) 0.3 (0.3) Adjusted EBITDA $ 250.8 $ 278.9 $ 245.6 $ 775.3 Weighted average common shares outstanding: Basic 99.0 99.0 99.0 99.0 Diluted 100.2 100.2 100.2 100.1 * Per share amounts for each period presented are based on diluted weighted-average shares outstanding. Refer to pages 48-49 for end notes.

Encompass Health 40 Reconciliation of net income to Adjusted EBITDA(7) 2020 Q1 Q2 Q3 Q4 Full Year (in millions, except per share data) Total Per Share Total Per Share Total Per Share Total Per Share Total Per Share Net Income $ 108.7 $ 48.3 $ 100.1 $ 111.7 $ 368.8 Loss (income) from disc ops, net of tax, attributable to Encompass Health 0.1 (0.1) — — — Net income attributable to noncontrolling interests (21.7) (14.8) (22.4) (25.7) (84.6) Income from continuing operations attributable to Encompass Health* 87.1 $ 0.87 33.4 $ 0.34 77.7 $ 0.78 86.0 $ 0.86 284.2 $ 2.85 Government, class action, and related settlements 2.8 — — — 2.8 Provision for income tax expense 27.1 11.8 26.9 38.0 103.8 Interest expense and amortization of debt discounts and fees 43.2 45.8 49.0 46.2 184.2 Depreciation and amortization 58.8 60.7 61.2 62.3 243.0 Loss on early extinguishment of debt(16) — — — 2.3 2.3 Loss on disposal or impairment of assets 0.1 3.0 7.5 1.0 11.6 Stock-based compensation expense 7.1 9.9 8.3 4.2 29.5 Gain on consolidation of former equity method location(2) (2.2) — — — (2.2) Change in fair market value of equity securities 2.5 (2.4) (0.4) (0.1) (0.4) Payroll taxes on SARs exercise(4) 1.5 — — — 1.5 Adjusted EBITDA $ 228.0 $ 162.2 $ 230.2 $ 239.9 $ 860.3 Weighted average common shares outstanding: Basic 98.2 98.7 98.7 98.7 98.6 Diluted 99.6 99.9 99.9 100.1 99.8 * Per share amounts for each period presented are based on diluted weighted-average shares outstanding. Refer to pages 48-49 for end notes.

Encompass Health 41 Net cash provided by operating activities reconciled to Adjusted EBITDA(7) Q3 9 Months Full Year (In Millions) 2021 2020 2021 2020 2020 Net cash provided by operating activities $ 177.6 $ 173.4 $ 592.0 $ 425.0 $ 704.7 Interest expense and amortization of debt discounts and fees 39.9 49.0 124.5 138.0 184.2 Equity in net income of nonconsolidated affiliates 0.9 1.0 2.9 2.5 3.5 Net income attributable to noncontrolling interests in continuing operations (26.7) (22.4) (80.9) (58.9) (84.6) Amortization of debt-related items (1.8) (2.0) (5.8) (5.1) (7.2) Distributions from nonconsolidated affiliates (0.9) (0.8) (2.7) (2.8) (3.8) Current portion of income tax expense 35.9 23.5 103.7 71.5 51.4 Change in assets and liabilities 16.0 7.2 27.0 47.7 7.3 Cash used in operating activities of discontinued operations — 0.1 0.6 0.2 0.2 Costs associated with the strategic alternatives review 4.6 — 9.6 — — Costs associated with the Frontier acquisition — — 1.3 — — Payroll taxes on SARs exercise(4) — — — 1.5 1.5 Change in fair market value of equity securities 0.3 (0.4) (0.3) (0.3) (0.4) Other (0.2) 1.6 3.4 1.1 3.5 Adjusted EBITDA $ 245.6 $ 230.2 $ 775.3 $ 620.4 $ 860.3 Refer to pages 48-49 for end notes.

Encompass Health 42 Reconciliation of segment Adjusted EBITDA to income from continuing operations before income tax expense Three Months Ended Nine Months Ended Year Ended September 30, September 30, December 31, 2021 2020 2021 2020 2020 (In Millions) Total segment Adjusted EBITDA $ 278.0 $ 261.0 $ 879.4 $ 712.8 $ 986.3 General and administrative expenses (43.9) (39.1) (136.7) (117.7) (155.5) Depreciation and amortization (64.9) (61.2) (190.8) (180.7) (243.0) Gain (loss) on disposal or impairment of assets 5.2 (7.5) 2.4 (10.6) (11.6) Government, class action, and related settlements(3) — — — (2.8) (2.8) Loss on early extinguishment of debt(1)(16) — — (1.0) — (2.3) Interest expense and amortization of debt discounts and fees (39.9) (49.0) (124.5) (138.0) (184.2) Net income attributable to noncontrolling interests 26.7 22.4 80.9 58.9 84.6 Change in fair market value of equity securities (0.3) 0.4 0.3 0.3 0.4 Gain on consolidation of former equity method location(2) — — — 2.2 2.2 Payroll taxes on SARs exercise(4) — — — (1.5) (1.5) Income from continuing operations before income tax expense $ 160.9 $ 127.0 $ 510.0 $ 322.9 $ 472.6 Refer to pages 48-49 for end notes.

Encompass Health 43 Reconciliation of net cash provided by operating activities to adjusted free cash flow(6) Q3 9 Months Full Year (In Millions) 2021 2020 2021 2020 2020 Net cash provided by operating activities $ 177.6 $ 173.4 $ 592.0 $ 425.0 $ 704.7 Impact of discontinued operations — 0.1 0.6 0.2 0.2 Net cash provided by operating activities of continuing operations 177.6 173.5 592.6 425.2 704.9 Capital expenditures for maintenance (32.1) (34.0) (85.9) (107.5) (154.9) Distributions paid to noncontrolling interests of consolidated affiliates (25.1) (15.4) (77.8) (52.9) (72.2) Items non-indicative of ongoing operating performance: Cash paid for SARs exercise (inclusive of payroll taxes)(4) — — — 102.1 102.1 Transaction costs and related assumed liabilities 3.7 — 8.2 — — Adjusted free cash flow $ 124.1 $ 124.1 $ 437.1 $ 366.9 $ 579.9 Cash dividends on common stock $ 27.8 $ 27.6 $ 84.7 $ 84.3 $ 111.9 Refer to pages 48-49 for end notes.

Encompass Health 44 Adjusted EPS(5) - Q3 2021 For the Three Months Ended September 30, 2021 Adjustments As Reported Income Tax Adjustments Costs Associated with the Strategic Alternatives Review Change in Fair Market Value of Equity Securities As Adjusted (In Millions, Except Per Share Amounts) Adjusted EBITDA $ 245.6 $ — $ — $ — $ 245.6 Depreciation and amortization (64.9) — — — (64.9) Interest expense and amortization of debt discounts and fees (39.9) — — — (39.9) Stock-based compensation (6.9) — — — (6.9) Gain on disposal or impairment of assets 5.2 — — — 5.2 Costs associated with the strategic alternatives review (4.6) — 4.6 — — Change in fair market value of equity securities (0.3) — — 0.3 — Income from continuing operations before income tax expense 134.2 — 4.6 0.3 139.1 Provision for income tax expense (34.1) (0.2) (1.2) (0.1) (35.6) Income from continuing operations attributable to Encompass Health $ 100.1 $ (0.2) $ 3.4 $ 0.2 $ 103.5 Diluted earnings per share from continuing operations* $ 1.00 $ — $ 0.03 $ — $ 1.03 Diluted shares used in calculation 100.2 * Adjusted EPS may not sum across due to rounding. Refer to pages 48-49 for end notes.

Encompass Health 45 For the Three Months Ended September 30, 2020 Adjustments As Reported Income Tax Adjustments Change in Fair Market Value of Equity Securities As Adjusted (In Millions, Except Per Share Amounts) Adjusted EBITDA $ 230.2 $ — $ — $ 230.2 Depreciation and amortization (61.2) — — (61.2) Interest expense and amortization of debt discounts and fees (49.0) — — (49.0) Stock-based compensation (8.3) — — (8.3) Loss on disposal or impairment of assets (7.5) — — (7.5) Change in fair market value of equity securities 0.4 — (0.4) — Income from continuing operations before income tax expense 104.6 — (0.4) 104.2 Provision for income tax expense (26.9) 0.1 0.1 (26.7) Income from continuing operations attributable to Encompass Health $ 77.7 $ 0.1 $ (0.3) $ 77.5 Diluted earnings per share from continuing operations* $ 0.78 $ — $ — $ 0.78 Diluted shares used in calculation 99.9 Adjusted EPS(5) - Q3 2020 * Adjusted EPS may not sum across due to rounding. Refer to pages 48-49 for end notes.

Encompass Health 46 For the Nine Months Ended September 30, 2021 Adjustments As Reported Loss on Early Exting. of Debt Income Tax Adjustments Costs Associated with the Strategic Alternatives Review Costs Associated with the Frontier Acquisition Change in Fair Market Value of Equity Securities As Adjusted (In Millions, Except Per Share Amounts) Adjusted EBITDA $ 775.3 $ — $ — $ — $ — $ — $ 775.3 Depreciation and amortization (190.8) — — — — — (190.8) Loss on early extinguishment of debt(1) (1.0) 1.0 — — — — — Interest expense and amortization of debt discounts and fees (124.5) — — — — — (124.5) Stock-based compensation (21.7) — — — — — (21.7) Gain on disposal or impairment of assets 2.4 — — — — — 2.4 Costs associated with the strategic alternatives review (9.6) — — 9.6 — — — Costs associated with the Frontier acquisition (1.3) — — — 1.3 — — Change in fair market value of equity securities 0.3 — — — — (0.3) — Income from continuing operations before income tax expense 429.1 1.0 — 9.6 1.3 (0.3) 440.7 Provision for income tax expense (108.1) (0.3) (3.6) (2.5) (0.3) 0.1 (114.7) Income from continuing operations attributable to Encompass Health $ 321.0 $ 0.7 $ (3.6) $ 7.1 $ 1.0 $ (0.2) $ 326.0 Diluted earnings per share from continuing operations* $ 3.20 $ 0.01 $ (0.04) $ 0.07 $ 0.01 $ — $ 3.26 Diluted shares used in calculation 100.1 Adjusted EPS(5) - YTD 2021 * Adjusted EPS may not sum across due to rounding. Refer to pages 48-49 for end notes.

Encompass Health 47 For the Nine Months Ended September 30, 2020 Adjustments As Reported Gov't, Class Action, & Related Settlements Income Tax Adjustments Change in Fair Market Value of Equity Securities Gain on Consolidation of Former Equity Method Location Payroll Taxes on SARs Exercise As Adjusted (In Millions, Except Per Share Amounts) Adjusted EBITDA $ 620.4 $ — $ — $ — $ — $ — $ 620.4 Depreciation and amortization (180.7) — — — — — (180.7) Government, class action, and related settlements(3) (2.8) 2.8 — — — — — Interest expense and amortization of debt discounts and fees (138.0) — — — — — (138.0) Stock-based compensation (25.3) — — — — — (25.3) Loss on disposal or impairments of assets (10.6) — — — — — (10.6) Change in fair market value of equity securities 0.3 — — (0.3) — — — Gain on consolidation of Treasure Coast(2) 2.2 — — — (2.2) — — Payroll taxes on SARs exercise(4) (1.5) — — — — 1.5 — Income from continuing operations before income tax expense 264.0 2.8 — (0.3) (2.2) 1.5 265.8 Provision for income tax expense (65.8) (0.7) (4.6) 0.1 0.6 (0.4) (70.8) Income from continuing operations attributable to Encompass Health $ 198.2 $ 2.1 $ (4.6) $ (0.2) $ (1.6) $ 1.1 $ 195.0 Diluted earnings per share from continuing operations* $ 1.99 $ 0.02 $ (0.05) $ — $ (0.02) $ 0.01 $ 1.96 Diluted shares used in calculation 99.7 Adjusted EPS(5) - YTD 2020 * Adjusted EPS may not sum across due to rounding. Refer to pages 48-49 for end notes.

Encompass Health 48 End notes (1) In the second quarter of 2021, the Company redeemed a total of $200 million of 5.125% Senior Notes due 2023 ($100 million in April and $100 million in June). The redemptions were completed at 100% of par using cash on hand and drawings under the Company’s revolving credit facility. As a result of the redemptions, the Company recorded a $1.0 million loss on early extinguishment of debt in the second quarter of 2021. (2) As a result of an amendment to the joint venture agreement related to our home health location in Treasure Coast, Florida, the accounting for this agency changed from the equity method of accounting to a consolidated entity effective January 1, 2020. We accounted for this change in control as a business combination and consolidated this entity using the acquisition method. As a result of our consolidation of this agency and the remeasurement of our previously held equity interest at fair value, we recorded a $2.2 million gain as part of other income in the first quarter of 2020. (3) As previously disclosed, from 2013 to 2019, the Company cooperated with an investigation of alleged improper or fraudulent Medicare and Medicaid claims. The investigation, under the direction of DOJ, produced no evidence of fraud, falsity or wrongdoing. However, based on discussions with DOJ, and having considered the burdens and distractions associated with continuing the investigation and the likely costs of future litigation, the Company estimated a settlement value of $48 million and accrued a loss contingency in that amount in the fourth quarter of 2018. Following further discussions, the Company entered into an agreement effective as of June 21, 2019 to settle all claims related to the DOJ investigation, together with related qui tam or “whistleblower” lawsuits, for cash payments totaling $48 million. (4) In connection with the 2014 acquisition of Encompass Home Health and Hospice, the Company granted stock appreciation rights (“SARs”) based on the fair value of the common stock of Home Health Holdings to certain members of that management team. Half of the SARs vested on Jan. 1, 2019, and the other half vested on Jan. 1, 2020. The fair value of the SARs was determined using the product of Home Health Holdings’ EBITDA for the trailing 12-month period and a median market price multiple based on a basket of public home health companies and recent transactions, less the current balance of any intracompany note to the parent. In Q1 2019 and Q3 2019, holders exercised vested SARs for cash proceeds of approximately $13 million and approximately $55 million, respectively. In Q1 2020, holders exercised the remaining SARs for cash proceeds of approximately $101 million. (5) The Company is providing adjusted earnings per share from continuing operations attributable to Encompass Health (“adjusted earnings per share”), which is a non- GAAP measure. The Company believes the presentation of adjusted earnings per share provides useful additional information to investors because it provides better comparability of ongoing operating performance to prior periods given that it excludes the impact of government, class action, and related settlements, professional fees - accounting, tax, and legal, mark-to-market adjustments for stock appreciation rights, gains or losses related to hedging and equity instruments, loss on early extinguishment of debt, adjustments to its income tax provision (such as valuation allowance adjustments, settlements of income tax claims and windfall tax benefits), items related to corporate and facility restructurings, and certain other items deemed to be non-indicative of ongoing operating performance. It is reasonable to expect that one or more of these excluded items will occur in future periods, but the amounts recognized can vary significantly from period to period and may not directly relate to the Company's ongoing operating performance. Accordingly, they can complicate comparisons of the Company's results of operations across periods and comparisons of the Company's results to those of other healthcare companies. Adjusted earnings per share should not be considered as a measure of financial performance under generally accepted accounting principles in the United States as the items excluded from it are significant components in understanding and assessing financial performance. Because adjusted earnings per share is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, it may not be comparable as presented to other similarly titled measures of other companies.* (6) Definition of adjusted free cash flow, which is a non-GAAP measure, is net cash provided by operating activities of continuing operations minus capital expenditures for maintenance, dividends paid on preferred stock, distributions to noncontrolling interests, and certain other items deemed to be non-indicative of ongoing operating performance. Common stock dividends are not included in the calculation of adjusted free cash flow. Because this measure is not determined in accordance with GAAP and is susceptible to varying calculations, it may not be comparable to other similarly titled measures presented by other companies. (7) Adjusted EBITDA is a non-GAAP financial measure. The Company’s leverage ratio (total consolidated debt to Adjusted EBITDA for the trailing four quarters) is, likewise, a non-GAAP measure. Management and some members of the investment community utilize Adjusted EBITDA as a financial measure and the leverage ratio as a liquidity measure on an ongoing basis. These measures are not recognized in accordance with GAAP and should not be viewed as an alternative to GAAP measures of performance or liquidity. In evaluating Adjusted EBITDA, the reader should be aware that in the future the Company may incur expenses similar to the adjustments set forth. (8) On Oct. 28, 2013, the Company announced its board of directors authorized the repurchase of up to $200 million of its common stock. On Feb. 14, 2014, the Company's board approved an increase in this common stock repurchase authorization from $200 million to $250 million. As of June 30, 2018, the remaining repurchase authorization was approximately $58 million. On July 24, 2018, the Company's board approved resetting the aggregate common stock repurchase authorization to $250 million. As of September 30, 2021, the remaining repurchase authorization was approximately $198 million. * Reconciliations to GAAP provided on pages 39-47.

Encompass Health 49 End notes, continued (9) As a result of negotiations with our partner to amend the joint venture agreement related to Yuma Rehabilitation Hospital, the accounting for this hospital changed from the equity method of accounting to a consolidated entity effective July 1, 2019. We accounted for this change in control as a business combination and consolidated this entity using the acquisition method. As a result of our consolidation of this hospital and the remeasurement of our previously held equity interest at fair value, we recorded a $19.2 million gain as part of other income in the third quarter of 2019. (10) Data provided by Uniform Data System for Medical Rehabilitation, a division of UB Foundation Activities, Inc., a data gathering and analysis organization for the rehabilitation industry; represents ~80% of industry, including Encompass Health inpatient rehabilitation sites (11) Represents discharges from 144 consolidated hospitals in Q3 2021; 140 consolidated hospitals in Q2 2021; 138 consolidated hospitals in Q1 2021; 137 consolidated hospitals in Q4 2020; 136 consolidated hospitals in Q3 and Q2 2020; and 134 consolidated hospitals in Q1 2020. (12) Full-time equivalents included in the table represent Encompass Health employees who participate in or support the operations of our hospitals and include an estimate of full-time equivalents related to contract labor. (13) Employees per occupied bed, or “EPOB,” is calculated by dividing the number of full-time equivalents, including an estimate of full-time equivalents from the utilization of contract labor, by the number of occupied beds during each period. The number of occupied beds is determined by multiplying the number of licensed beds by the Company’s occupancy percentage. (14) Represents home health admissions from 248 consolidated locations in Q3 2021 and Q2 2021; 240 consolidated locations in Q1 2021 and Q4 2020; 241 consolidated locations in Q3 2020; 244 consolidated locations in Q2 and Q1 2020. (15) Represents hospice admissions from 95 locations in Q3 2021; 94 locations in Q2 2021; 82 locations in Q1 2021 and Q4 2020; 83 locations in Q3, Q2 and Q1 2020. (16) In October 2020, the Company issued $400 million of 4.625% Senior Notes due 2031. The proceeds plus approximately $300 million of cash on hand were used to fully redeem $700 million of 5.75% Senior Notes due 2024 at par on November 1, 2020. As a result of this redemption, the Company recorded an approximate $2 million loss on early extinguishment of debt in the fourth quarter of 2020.